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 Quantitative Structure-Activity Relationship (QSAR) methods are a commonly 
used tool in the drug discovery process.  These methods attempt to form a statistical 
model that relates descriptor properties of a ligand to the activity of that ligand compound 
towards a specific desired physiological response.  QSAR methods are known as a 
ligand-based method, as they specifically use information from ligands and not protein 
structural data.  However, a derivation of QSAR methods are pseudoreceptor methods.  
Pseudoreceptor methods go beyond standard QSAR by building a model representation 
of the protein pocket.  However, the ability of pseudoreceptors to accurately replicate 
natural protein surfaces has not been studied.    The goal of this thesis work is to 
investigate the necessary descriptors to map a protein binding pocket and a method to 
accurately recreate the 3-D spatial structure of the binding pocket.  In addition, additional 
applications of existing pseudoreceptor methods are explored. 
 To identify the necessary descriptors to map a protein binding pocket,   we 
developed a program that decomposes the protein-ligand interaction surface from a large 







structure are identified, and then the physico-chemical properties of the protein are 
mapped onto the solvent accessible surface of the binding pocket.  A number of 2-D 
Gaussian functions are then placed onto this surface to model the protein’s physico-
chemical properties.  We found that a small number of these Gaussians were able to 
accurately replicate the properties of the protein. 
 With this knowledge, we then desired a means of accurately recreating the 
binding pocket surfaces of proteins only the structures of their bound ligands.  Typically 
in pseudoreceptor methods either the average or combined solvent accessible surface of 
the ligand set is used.  To test this, we generated iso-level surfaces of the solvent 
accessible surfaces of sets of ligands for which the co-crystallized protein structure is 
available.  We also tested additional sets of surfaces located beyond the ligand’s solvent 
accessible surface.  We found that any single surface was unable to accurately reproduce 
the protein-ligand interaction surface, and multi-surface approach using numerous iso-
surfaces is needed to accurately represent the protein. 
 Finally, we explored the application of RAPTOR, an existing pseudoreceptor 
method, to the problem of the prediction of Sites-of-Metabolism (SoM) for Cytochrome 
P450s (Cyps).  In our approach, we used RAPTOR as a means of discriminating between 
active (correctly predicted SoM) docking poses of ligands from decoy (incorrect SoM) 
poses.  With our method, we achieved the highest reported rate of SoM prediction across 






CHAPTER 1. INTRODUCTION 
1.1 Combined Ligand-based and Structure-based Computer-Aided Drug Design 
The majority of Computer-Aided Drug Design (CADD) methods can be divided into 
two categories: ligand-based drug design, and structure-based drug design.   These 
categories are named after the origin of the data used in the design procedure.  Ligand-
based drug design efforts are based off the analysis of the biological activities and chemical 
properties of a set of ligands, and are often used when little to no information about the 
structure of the target protein is available.  A primary example of ligand-based drug design 
would be the wide variety of Quantitative Structure Activity Relationship (QSAR) 
techniques.  On the other hand, when there is sufficient information about the three-
dimensional structure of the target protein, especially if an X-ray structure is available, 
structure-based drug design methods are routinely applied in the drug development process.  
These techniques focus on simulating the interactions of potential ligands with the protein 
structure.  Molecular dynamics or Monte Carlo simulation-based free energy methods and 
protein-ligand docking simulations are major types of structure-based design techniques.  
However, as the number of available protein-ligand crystal structures continues to rise, and 
as more and more physicochemical and biological data for ligands is published, there is an 
increasing number of systems where both ligand and protein structure data is available.  






perform both ligand-based and structure-based drug design on the same protein system.  
These efforts may be as simple as performing QSAR or pharmacophore studies and 
docking on the same system, and there are a number of examples of such occurrences in 
the literature1,2.   What we are focused on here, however, are integrated methods of 
combining ligand-based and structure-based drug design concepts into a single technique. 
 Some of the earliest work on combining techniques from structure- and ligand-
based design was the adaptation of the GRID program3,4 to ligand-based design leading to 
the GRID-GOLPE approach5.  The GRID method can be used on a protein structure to 
identify hotspots of possible protein-ligand interactions, e.g. favorable interactions with 
hydrogen-bonding or hydrophobic groups.  In the GRID-GOLPE adaptation, GRID is 
applied on a set of ligand structures binding to a common binding site. GOLPE6 performs 
the chemometric analysis by identifying the descriptors strongly correlating with biological 
activity and generating a multivariate regression using those descriptors.  The methods that 
we will discuss in this section cover two major categories where significant development 
of integrated structure-based and ligand-based drug design is occurring: interaction-based 








Figure 1.1: Classification scheme of integrated structure and ligand-based methods.  The 
major classification into two major categories includes interaction-based and docking 
similarity-based methods.  Each of those categories contain two subcategories: 
pseudoreceptor methods and pharmacophore/fingerprint-based methods for the 
interaction-based methods, and combined structure-ligand based virtual screening 
approaches and methods that integrate similarity-based concepts into the scoring process 
of ligand docking. 
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1.1.1 Interaction-Based Methods 
One major class of methods integrating both ligand-based and structure-based drug 
design methods is based on comparing or modeling protein-ligand interactions across 
similar protein-ligand systems.  These concepts seek to identify key protein-ligand 
interactions from known data and utilize this interaction data to identify ligands with 
similar interaction profile.  This class of integrated methods can be further divided into two 
sub-categories (Figure 1.1).  The first sub-category is the pseudoreceptor techniques that 
correlate similarities between ligands with measured biological activity, similar to QSAR, 
but then use this data to establish a structural representation of the protein-ligand binding 
pocket11,45,46,48,50-72.  The other set of techniques is the converse of the first category.  These 
methods analyze protein-ligand interactions in structural data to extract key types of 
interactions, and then translate that information into a simplified mathematical 
representation that can be used by similarity-based methods to screen for active lead 
compounds in ligand libraries73-96.  Many techniques from this category are based upon 
fingerprint or pharmacophore models. 
 
1.1.2 Docking and Screening Based Methods 
 The second major class of integrated structure-based and ligand-based design 
techniques is those methods which combine structure-based docking techniques with 
ligand-based similarity information (Figure 1.1)2,97-104.  The first subcategory is screening-
based methods.  These methods use ligand similarity to aid high-throughput virtual 
screening in one of two ways.  When there is a known hit or lead compound, similarity 






docked.   The other approach is to use docking to identify a possible hit, and then screen a 
ligand library for similar ligands as alternative hits.   The other category addresses one of 
the major known issues with docking, the scoring problem, by integrating ligand similarity 
directly into the scoring process. 
 
1.2 Pseudoreceptor Methods 
As mentioned previously, pseudoreceptor methods are a means of integrating 
structure-based and ligand-based techniques.  Pseudoreceptor7 methods are primarily 
expansions of Quantitative Structure Activity Relationship (QSAR) techniques, mainly 3-
D-QSAR techniques such as CoMFA8, CoMSIA9,10, or GOLPE6, that place 
physicochemical information onto 3-D space surrounding a set of aligned reference 
compounds that bind into the same binding site of a common macromolecular target.  
Pseudoreceptor methods expand this mapping by attempting to create models of the target 
protein binding site around the ligand ensemble.  These representative pseudoreceptor 
models are intended to contain key protein-ligand interactions, and to map these 
interactions into an appropriate shape and volume.   
The aim of generating these models is to be able to rationally modify or propose 
new small molecules that are complementary to the pseudoreceptor model and to 
accurately predict binding affinities for a series of potential ligands.  Early pseudoreceptor 
methods involved the manual folding of peptide chains around the ligand ensemble11, but 
these methods have now been expanded into a wide-variety of automated computational 
methods.  There are several major classes of pseudoreceptor methods including atom-based, 






1.2.1 Challenges of Pseudoreceptor Methods 
Two critical factors in the overall process of pseudoreceptor modeling are the 
chemical space of the ligand set and the ligand alignment process.  The chemical space of 
a ligand set refers to the set of physicochemical properties present in the entire ligand 
library and the span of related binding affinities.  The pseudoreceptor model can only 
account for those features present in the chemical space of the ligand library, e.g. if a 
protein has a hydrogen-bonding residue in the binding pocket with no matching functional 
group in the ligand set, the pseudoreceptor model will lack that particular hydrogen-
bonding feature.   
The alignment of the ligand set plays an important role in generating the 
pseudoreceptor model as well.  In order to accurately represent the 3-D structure of the 
protein-binding pocket, the correct ligand binding mode is necessary.  This is a non-trivial 
challenge, especially with regards to highly flexible ligands.  As such, a large number of 
methods for alignment have been developed and utilized for the various pseudoreceptor 
methods.  Alignment techniques include pharmacophore based methods, molecular 
simulations, other similarity-based methods, as well as docking methods if protein structure 
information is available12-21.   
 
1.2.2 Surface-based methods 
One major class of pseudoreceptors is surface-based methods, where the 
pseudoreceptor is represented as a curved 3-D surface with physicochemical properties 
mapped onto it representing protein properties important for protein-ligand interactions44-






a “shape field” for each ligand is generated that represents the molecular volume45-47.  The 
fields for all ligands are then combined, and an iso-level surface is generated based on the 
combined shape field.  In RAPTOR, an iso-surface approximating the solvent-accessible 
surface of the aligned ligand-set is generated48.  The occupancy of every ligand atom is 
mapped onto a grid according to a smooth function ranging from one at the atom center to 
zero at its solvent accessible surface. An iso-level surface is then generated again, similar 
to the RSM approach.   
 
1.3 Cytochrome P450 
 Cytochromes P450 (CYPs) are a superfamily of membrane-bound hemoproteins.  
They are enzymes, with a heme-iron catalytic site with the iron coordinated via a cysteine 
residue.  CYPs, generally, catalyze the oxidation of a substrate via electron transfer and 
hydrogen abstraction.  CYPs are membrane-anchored proteins, with molecular weights 
ranging from 45 to 60 kDa, and they contain large, flexible binding pockets.  While CYPs 
are found in a wide variety of species, the human cytochromes are encoded by 57 genes 






1.3.1 Importance of Cytochrome P450 
 CYPs metabolize both endogenous and exogenous compounds22, which leads to 
their clinical importance: the CYP superfamily is responsible for the metabolism of the 
majority of pharmaceutical compounds23.  Particularly important in drug metabolism are 
CYP1A2, CYP2C9, CYP2C19, CYP2-D6, and CYP3A424.   As drug metabolism and 
elimination are important factors in the drug discovery and development process, and CYPs 
play a ubiquitous role in those processes, CYP-drug interactions must be kept constantly 
in mind when developing new pharmaceuticals25.  Common concerns are metabolic rate, 
which is a key factor in therapeutic dosage, and the production of toxic metabolites, which 
can cause the abandonment of otherwise promising drug candidates26.  These concerns lead 
to the desire of medicinal chemists for the ability to alter metabolic rate or by-product 
production by changing the site of ligand metabolism via CYPs27,28. 
 
1.3.2 Site of Metabolism Prediction 
 In order to alter the metabolism of a ligand by CYP, one must be able to predict the 
ligands’ sites of metabolism (SoM).  Computational tools have become widely used for the 
prediction of SoM of CYP substrates27.  As mentioned previously, computational methods 
are divided into structure-based, ligand-based, and combined methods, and there exists 










  1.3.2.1 Ligand-based Site of Metabolism Prediction 
 Ligand-based techniques, as mentioned previously, analyze ligands’ 
physicochemical properties to predict the most likely site of metabolism.  Such methods 
include quantum chemical calculation-based reactivity prediction, such as SmartCYP31, 
pharmacophore models, rule-based methods, and fingerprint methods32.  While highly 
efficient, these methods also ignore important considerations, namely the binding pose of 
the ligand with its target CYP, as the most energetically favorable metabolic site may not 
be located in proximity to the catalytic heme. 
 
1.3.2.2 Structure-based Site of Metabolism Prediction 
 The converse to ligand-based techniques, structure-based techniques calculate 
interactions between a ligand and a structural model of the CYP enzyme to determine the 
likely SoM.  Structure-based techniques include ligand docking and molecular dynamics 
simulations33.  These techniques attempt to predict if a ligand will bind a specific CYP 
enzyme, and if so, attempt to determine the binding pose of the ligand and which ligand 
atoms are in close proximity to the catalytic heme.  These techniques can be time 
consuming, especially molecular dynamics simulations, and are highly dependent on the 
accuracy of the scoring function or force field used in the simulations and require protein 
structure models, which can be difficult to obtain, especially for membrane-bound proteins 










1.3.2.3. Combined Ligand-based and Structure-based Site of Metabolism Prediction 
 As mentioned previously, both ligand-based and structure-based methods have 
significant weakness when predicting SoMs.  This has led many groups34-38, including the 
Lill group39, to attempt to combine both types of methods.  These combined methods are 
designed to utilize ligand-based information while being guided by structural constraints.  
These methods are especially useful when multiple metabolic pathways exist for a 
compound.  An exemplar of this situation is the compound Terbinafine, which is 
metabolized by at least seven different CYP isozymes and results in multiple different 
metabolites40.   The complex interactions between reactivity and ligand-binding pose are 
difficult to predict using structure-based or ligand-based information only. 
 The approach previously developed by the Lill group combined the NAT reactivity 
model developed by Olsen et al.41 with ensemble docking.  In ensemble docking, molecular 
dynamics simulations are performed on a protein crystal structure to produce a diverse 
ensemble of protein structures.  The ligands of interest are then docked to every member 
of the protein ensemble instead of a single crystal structure.  This allows for protein 
flexibility to generate a more diverse set of ligand binding poses.  In our previous method, 
instead of purely relying on the docking scoring function to determine the best scoring pose, 
and therefore the predicted site of metabolism as determined by proximity to the catalytic 
site, the NAT model was included as an additional scoring factor.  This skewed the results 
towards those poses with a reactively favored atom close to the metabolic heme, and 









1.4 Research Summary 
 The overall goal of my research is the application and development of the 
advancement of combined ligand-based and structure-based techniques, namely 
pseudoreceptor-based methods, with a focus on surface-based pseudoreceptors.  While the 
goal of pseudoreceptor methods is to produce a protein-like structure to interact with 
ligands, there has been a lack of use of protein structural data in the guiding of the creation 
of the pseudoreceptors.  In Chapter 2, analysis of the interaction surface between protein 
crystal structure and co-crystallized ligand for the refined set of the PDBbind database42,43 
will be presented.   These surfaces represent the ideal pseudoreceptor, as they map the true 
interactions of protein and ligand, and the analysis will show that the majority of protein-
ligand interactions can be mapped by a few of Gaussian-based descriptors that have 
parameters that fall into a small range of values.  In Chapter 3, a means of tuning surface-
based pseudoreceptors to accurately replicate protein binding pocket topology as from 
known binding ligands will be presented. 
In Chapter 4, I will discuss the implementation of the refinement of our group’s 
previous work on SoM prediction, which includes the use of a modified version of the 
RAPTOR pseudoreceptor package.  The modification was the inclusion of reactivity scores 
from the SMARTCYP package as term in the RAPTOR scoring function.   The motivation 
for the inclusion of RAPTOR was as a means of generating a model which could reliably 
select binding poses with the known SoM close to the heme of CYP.  This method was 
implemented as a means to counteract the difficulties arising from the large number of 
poses generated by the ensemble docking process.  The initial modeling was performed on 







***Note: Portions of this section previously published in the following papers: 
Wilson, GL.; Lill, MA. Integrating structure-based and ligand-based approaches for 
computational drug design, Future Medicinal Chemistry, 2011, 3, 735-770. 
Wilson, GL.; Lill, MA. Towards a realistic representation in surface-based 
pseudoreceptor modelling: a PDB-wide analysis of binding pockets, Molecular 
Informatics, 2012, 31, 259-271 
Kingsley, LJ.; Wilson, GL.; Essex, ME.; Lill, MA. Combining Structure- and Ligand-
Based Approaches to Improve Site of Metabolism Prediction in CYP2C9 Substrates. 
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Pseudoreceptor models are intended to contain key protein–ligand interactions, 
and to map the appropriate spatial information content of these interactions. The aim 
of pseudoreceptor modelling is to generate surrogates of the 3-D structure of the 
protein binding site that can be used for structure-based drug design applications such 
as virtual screening, rationally modifying or proposing new small molecules 
complementary to the pseudoreceptor model, and predicting binding affinities of 
potential ligands. Although several types of pseudoreceptor representations exist1,2, 
one popular class are surface-based pseudoreceptor models that represent the binding 
site of the target protein by selected surfaces. Of particular interest is the solvent -
accessible surface, as it represents the 3-D-space most critical for the complementary 
contacts between protein and ligand. Hydrogen bonds and van der Waals interactions 
are particularly strong at the protein-ligand interface. Thus, these surfaces can provide 
a rather complete representation of the protein-ligand contacts while reducing the 







The method RAPTOR11 is an example of a surface- based pseudoreceptor 
approach. Additionally, RAPTOR accounts for both ligand and protein flexibility. In 
general the RAPTOR algorithm works by distributing hydrophobic and hydrogen 
bond properties representing the surrogate of the target protein onto a surface 
surrounding an aligned set of ligand molecules until the interaction between these 
surface properties and the ligands reproduces the experimental binding affinities of 
the compounds. A scoring function is then utilized to measure the interaction strength 
between surface properties and ligand atoms. 
The critical question is how the different physicochemical properties are 
distributed onto the pseudoreceptor surface. In methods such as RAPTOR the surface 
is typically represented by several hundred points. In the most naïve approach those 
points are treated independently from each other, and overfitting may occur during 
optimization of the pseudoreceptor model.  To reduce the number of descriptors in 
RAPTOR, we defined patches of surface points that were empirically forced to adopt 
similar physicochemical properties. The patch size and the transition between patches, 
however, are user-defined and may not reflect accurately the distribution of physico-
chemical properties in experimental protein structures.   
In this chapter, we address the question if the physico-chemical properties on 
the solvent-accessible surface of experimentally determined protein structures can be 
accurately modelled by a small number of surface descriptors.  First, we analysed 
binding pocket surfaces of a large set of experimentally determined protein-ligand 
complexes and used 2-D Gaussian functions to fit the surface properties.  The fitted 







six Gaussian functions are necessary to model each surface property. These 
descriptors will allow for a more realistic pseudoreceptor representation of the 
binding site compared to our current empirical patching model implemented in 
RAPTOR and limit the number of descriptors, thereby reducing the potential of 
overfitting throughout the QSAR optimization phase.  
 
2.2 Database Preparation 
For our analysis of protein-ligand interaction surfaces the PDBBind Database3,4 
was chosen, as it contains target protein structures co-crystallized with small molecule 
ligands.  The refined set of the PDBBind database, a set of protein-small molecule crystal 
complexes manually reviewed for resolution, binding affinity data, protein amino acid 
composition, and ligand molecular and common element composition criteria, was 
prepared as input data to our Protein-Ligand Surface Interaction Analysis (PLSIA) program 
(see next section).  The REDUCE program5 was utilized to add missing atoms to the PDB 
structures and to optimize the protein’s hydrogen-bond network by adjusting Asn, Gln and 
His side-chain orientations, as well as the tautomeric and protonation state of His residues. 
AMBER atom types and partial charges were then assigned to the optimized protein 
structures using the AMBER036 force field parameter file. Parameters were not assigned 








2.3 PLSIA Algorithm 
2.3.1 Surface Triangulation 
The Protein-Ligand Surface Interaction Analysis (PLSIA) program operated by 
loading each protein structure and generating a separate PDB file in which the ligand has 
been removed.  The pseudo-holo form was used for the calculation of triangulated surfaces 
on the exterior protein surface and any cavity using the MSRoll program7.  MSRoll uses a 
rolling probe method to determine the solvent-accessible surface. The cavity or surface 
closest to the ligand was identified using a distance calculation between the ligand atoms 
and the closest surface points and was selected as the protein- ligand interaction surface.  
In order to produce a surface with a larger number of smaller triangles, the tessellation 
fitness parameter was set to 0.5 radians, the default settings were used for all additional 
parameters.   
MSRoll generated a triangulated representation of each exterior and cavity surface, 
however, the triangulation is often heterogeneous, with triangles varying significantly in 
size. The COALESCE program8 was used to regularize the triangulated surfaces. 
COALESCE loads the MSRoll output and combines small triangles, those with edges with 
less than half the average edge length (which is typically around 0.5 Å), and fixes dangling 
vertices resulting in a smooth triangulated surface with similar triangle sizes. COALESCE 
also standardizes the direction of the normal vectors of each triangle, always pointing away 
from the protein. After this refinement, all triangle vertices more than 8 Å from any ligand 








2.3.2 Protein Property Calculation 
After identifying and isolating the binding pocket surface, the program PLSIA 
determined the electrostatic, hydrogen bond, and hydrophobic field of the protein mapped 
onto each triangle vertex.  The results of these equations were parameterized such that an 
output value of one is approximately one kcal/mol of interaction energy. 
 
2.3.2.1 Electrostatic Calculations 
In PLSIA a partial charge was assigned to each protein atom using the Amber03 
force field.  The Coulombic potential on each surface vertex, s, generated by the protein 











         (2.1) 
Here, n is the number of protein atoms within 12 Å of the surface point s, qi is the partial 
charge of protein atom i, and D(rsi) is the distance-dependent dielectric, which in this case 
is rsi itself, and rsi is the distance between the vertex s and atom i. 
 
2.3.2.2 Hydrogen Bond Calculations 
All protein atoms capable of forming hydrogen-bonds were identified in PLSIA.  
Next, the availability of the donors and acceptors to form protein-ligand hydrogen bonds 
was determined. Donors and acceptors form intra-protein hydrogen bonds if there was a 
complimentary hydrogen-bonding partner identified within 2.5Å and a maximum angle of 
40 degrees between the donor hydrogen atom, donor heavy atom and the acceptor atom.  







for further calculation of the hydrogen-bond fields on the protein surface.  Accessible 
hydrogen bonding protein atoms that were within 4 Å of a surface vertex were used to 
calculate the hydrogen bond potential on the vertex point s using the following equation: 




















,;         (2.2b) 
Here, rsi is the distance between the vertex s and the hydrogen bond partner 
(hydrogen for donor and heteroatom for acceptor), and  is the hydrogen bond angle.  
For hydrogen bond donors, this angle is between the donor hydrogen atom, the donor 
heavy atom, and the vertex. For hydrogen bond acceptors, the angle is between the 
acceptor’s lone pair, the acceptor atom, and the vertex. The donor potential and 
acceptor potential were determined separately, and a value for both was assigned to 
each vertex.  In addition, the protein atoms which provided the strongest contribution 
to each vertex were identified and stored. 
 
2.3.2.3 Hydrophobic Calculations 
PLSIA assigned a partial logP value to each protein atom using the methodology 
of Wildman and Crippen9.  The overall hydrophobic field spawned by all protein atoms 

















Here, n is the number of protein atoms within 3 Å of the vertex s, logPi is the partial 
log P value of protein atom i, and rsi is the distance between the vertex s and atom i. 
 
2.3.3 Gaussian Preparation 
After the physico-chemical properties of interest have been mapped onto the vertex 
points of the solvent-accessible  surface of the protein, several calculations had to be 
performed to project the 3-D surface onto a 2-D projection map allowing subsequent  2-D 
fits using  Gaussian  network models (see section 2.2.6).  First, an analysis of the 
connectivity of the vertex points was performed to generate the Shortest Path Array (SPA).  
This array was an NxN matrix, where N is the number of surface vertex points, describing 
the shortest connectivity between two vertices along the edges of the triangulated surface.  
The generation of the SPA involved the use of an NxN Edge matrix in which all vertices i 
and j, that are connected via an edge of the triangulated surface were assigned a value of 
one to their corresponding entries Edgei,j and Edgej,i  in the Edge matrix. All entries Edgei,j 
that corresponded to unconnected vertices i and j were set to zero. A brute-force search 
along the connected edges between all vertices using the Edge matrix was used to calculate 
the smallest number of edges separating two vertices, and this value was stored in the SPA.  









Figure 2.1: Possible paths for vertices separated by three edges. Central path which 








Next, the relative coordinates of the surface points in 3-D representation of the 
protein surface were projected into a 2-D representation to allow for a fit with 2-D 
Gaussian functions:  PLSIA approximates the 2-D distance along the interaction 
surfaces (Figure 2.1).  This calculation was trivial for adjacent vertices (Figure 2.1, 
points A, B), but became more complicated for more separated surface vertex points.  
For all adjacent vertex points, the direct 3-D distance between the two vertex points 
was calculated and stored.   
For points (Figure 2.1, points A, C) separated by two edges (SPA = 2), the 
following process was used:  First, all intermediate points were identified that are 
directly connected to the two target vertices (SPA = 1).  Due to the triangulation of 
the surface, some vertices shared two intermediate po ints (B, D).  For those cases, the 
distance between the two target vertices was defined by finding the point on the 
intermediate edge point (E) that had the smallest sum of distances to the target vertices 
(A, C).  This distance was determined computing the smallest distance along the 
triangulated surface between points A and C passing through 100 equally separated 
points along the edge BD.  This represented the shortest path along the triangulated 
surface between the target vertices (A, C) for a given pair of intermediates (B, D).  
This distance was computed for all vertices with SPA = 2, and the shortest distance 
for each pair was stored.  For points separated by successively higher SPA values, the 
distance was determined by finding the shortest distance given a single intermediate 
point: For vertices with 3 edge separations (SPA = 3; Figure 2.1, points A, F) all 
intermediates with an SPA = 1 to a target vertex (e.g. CF, GF) and an edge with SPA 







separations of all  SPA=3/SPA=1 and SPA=2/SPA=2 pairings were compared and the 
shortest distance for each target vertex pair was stored. This procedure was then 
generalized for larger edge separations.   
 
2.3.4 Patching Process 
Next, the surface was divided into patches that represent local maxima of the 
physico-chemical properties that were subsequently fitted using Gaussian functions (see 
section 2.2.6).  This patching was accomplished by the following process:  First, dependent 
on the studied property, the maximum or minimum value of the property on a vertex was 
identified, and this vertex was defined to be the origin of the first patch.  Starting from this 
origin vertex, the vertices with increasing separation from the origin were examined: First 
all vertices with SPA=1, then SPA=2, etc. were examined to determine if they are added 
to the current patch, until an empirically defined maximum edge separation of nine was 
reached.   
In order for a vertex to be included in the current patch, it must have fulfilled 
a number of conditions:  First, the absolute value of the property had to exceed a 
certain minimum property value, set to 0.1 kcal/mol for all properties, except 
hydrophobicity which was set to 0.05 kcal/mol.  This condition was introduced to 
limit the patches to those vertices that represent significant magnitudes of the 
properties of interest.  This condition also allowed for the separation of the 
electrostatic potential into patches with positive and negative values using zero, or 
more precisely the region between -0.1 and 0.1 kcal/mol as boundary criteria.  The 







vertex already included in the patch definition.  This condition was used to prevent 
two nearby, but separated patches from being combined into a single patch.  The third 
condition for defining a patch was that it must contain at least four vertices, as that is 
the minimum number of points required to fit a 2-D Gaussian containing four 
variables (see section 2.3.6).  Additionally, the hydrogen bonding parameters had a 
fourth patching criterion: all members of a patch had to share the same strongest 
contributing protein atom as identified in the property calculation process.  This 
condition aided in separating overlapping hydrogen bonding patches caused by 
different hydrogen-bonding protein groups. 
 
2.3.5 Coordinate Transformation 
The final step prior to the Gaussian fit was the transformation of the 3-D 
coordinates of the surface vertices of a patch to 2-D coordinates (Figure 2.2).  The 
following list details the process of this transformation. 
1. The center of the patch was defined as the origin (O) 
2. The normal vector of the origin (ON) was calculated by averaging the normal 
vectors of all triangles of which O is a member. 
3. A transformation plane was defined by the plane that passes through O and is 
perpendicular to ON. 
4. All other vertices of the patch were projected into this plane along the vectors 
normal to the plane (e.g. C  C’ or A  A’). 
5. A reference axis for use with 2-D polar coordinates was defined by the vector 







6. Using this reference axis and the normal vector of the plane, angles for each of the 
projected vertices were determined (Figure 2.2). 
7. The surface distance between each vertex A and O was looked up from the data 
calculated in section 2.2.3. 
8. A new point B’ was calculated for each A by moving the distance from step 7 along 
the angle from step 6. (e.g. Point B’ has coordinates (DistOA, (A’OC’)). 
9. Using these polar coordinates each new vertex was translated into 2-D Cartesian 
coordinates with the origin vertex O having coordinates (0, 0) for use as a reference 









Figure 2.2: Projection of vertices on 3D surface patch into the 2D plane defined by the 
origin vertex O (maximum or minimum property value) and its normal vector. 3D 
vertices, e.g. A, are projected into the plane (A’) and are scaled to match the 3D 








2.3.6 Gaussian Fitting Process 
Once all surface vertices of the patch were translated into 2-D Cartesian 
coordinate form (x,y), a standard multivariate fitting algorithms was applied to fit a 
2-D Gaussian function to each patch: 



































   
with σx representing one axis of the Gaussian, σy the remaining axis, θ is rotation of 
the Gaussian axes with respect to the standard Cartesian axes, and A is the amplitude 
of the Gaussian.   
   PLSIA used the non-linear least-squares fitting algorithm from the GNU 
Scientific Library10, based on the Levenberg-Marquadt algorithm, to fit a standard 2-
D Gaussian function to each patch.  The fitting process was run for 10000 steps and 
was repeated for up to 81 different initial parameter settings.  Each parameter, 
amplitude, θ, σx, and σy, had three possible initial settings: 0.25, 0.75, 1.5. Different 
permutations of these starting parameters were run until the Gaussian fit converged 
to a solution with a low sum square error (the average percent error across the patch 
is less than 10%) or until all 81 initial parameter sets had been evaluated, in which 








2.3.7 Iteration and Re-patching Process 
After fitting the first patch, the patching and fitting process continued according to 
two different schemes. In the first scheme, called One Pass Fit patching, all vertices of the 
previously fitted patch were removed from further consideration for subsequent patching 
and Gaussian fitting.  The patching and fitting process was repeated for all remaining 
vertices until no further vertices meet the patch criteria.  In this scheme, each point was 
fitted to a Gaussian function at most once for any studied physico-chemical property. 
The second scheme, called Residual Fit patching, allowed for each vertex to 
be fitted multiple times.  This was done to see if the surface was more accurately 
represented by one patch per property per surface region or multiple overlapping 
patches.  This occurs by subtracting the physico-chemical values of the Gaussian fit 
from the original value for every vertex of the current patch resulting in residual 
values.  These residual values were then assigned to each vertex and the modified 
vertices were further considered in the patching algorithm as viable candidates.  
 
2.3.8 Clique Detection Analysis Using Patch Centers 
The Gaussian functions fitted to the patches model the physico-chemical properties 
of the protein projected onto its surface. We expect similar properties on the surface for the 
same protein bound to different ligands if no significant conformational change occurs. To 
test this hypothesis, we performed clique detection between the patch centers for each pair 
of proteins. The center points of the Gaussian fits produced by the PLSIA program were 







protein surface was generated storing the distances and center types (e.g. donor-donor, 
donor-acceptor, etc.) for all pairs of centers.   
These arrays were used in a clique detection algorithm performing an 
exhaustive search to identify the maximum number of patch centres for which all 
pairwise distances between the two proteins match.  A distance between two centers 
was considered a match if the distances for the two proteins were within a user -
defined tolerance of 0.75 Å and if the centers had matching corresponding property 
types.  A score S was computed for each pair of proteins i and j to measure the number 









S          (2.5) 
where nij
centers is the number of matching centers in the clique and ni
centers is the 
number of centers for protein i.  The number of matching centers was normalized by 
the smaller number of total centers of the two compared protein in order to correct for 
the variation in binding pocket size due to variation in size of the co-crystallized 
ligands.    
 
2.4 PLSIA Results 
2.4.1 Quality of Fit 
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Ep represents the average relative deviation over n evaluated vertices for a property p 
between the fitted values Fi at vertex i and computed initial surface value Ci at vertex 
i. We used this criterion to evaluate two different analysis schemes using PLSIA, One 
Pass and Residual Fit, as described under Section 2.3.7. 
Table 2.1 displays the average relative error of Gaussian fitting for 
electrostatic, hydrophobic and hydrogen properties. For electrostatic and hydrophobic 
properties, the average error is approximately 15% of the initial surface values, 
however larger errors are observed for donor and acceptor properties. This suggests 
that the patches can be represented by single Gaussians.  We propose that this 
difference in fitting accuracy between hydrogen-bond and the other properties is at 
least partially due to the directionality of the hydrogen bond (Figure 2.5).  If the 
hydrogen bond is oriented along the normal vector of the surface, the resulting patch 
is well characterized by a symmetric function such as the Gaussian function, as with 
increasing surface distance from the center of the patch both distance and angle 
increase reducing the interaction potential according to equation 2.2.  However, if the 
hydrogen bond direction is tilted with respect to the surface normal (Figure 2.5), the 
distance and angle term in equation 2.2 display different maxima on the surface and 







Table 2.1: Average Relative Error of Gaussian Fitting for Individual Properties  
Algorithm El.st. H.phobic Donor Acceptor 
One Pass Fit 0.159 0.156 0.254 0.225 








Figure 2.3: Hydrogen-bond interaction potential on the surface using equation 2 
together with the optimal Gaussian fit to that distribution for a single hydrogen bond 
group tilted with respect to the surface normal by 45 degrees. The hydrogen bond 
group is located two units below the axis at x=0.  The angle causes the potential 
function to have maximum not located at the coordinate center (x=0).  The error using 








We also observed that for all properties there is only a small difference in average 
relative errors between the One Pass and Residual fits.  Additionally, we investigated 
the effect of two central variables in the program, the minimum and maximum sizes 
of the fitted surface patch, onto the observed error in fit. The absolute minimum size 
of a patch is four points, as that is the number of unknown variables in the Gaussian 
function.  Changing the minimum size (Table 2.2) showed significant variation in the 
error of the fits.  Some of the error is due to several small patches that are being less 
well fit by Gaussian functions when a larger patch size is enforced. Consequently, we 
chose a minimum size of four points for subsequent analysis.  
The maximum size of the property patch is governed by the maximum number of 
edge lengths measured from the surface point representing the maximum value of a 
property of a patch.  We investigated maximum edge lengths of five to nine edges 
using the Residual Fit method.  Comparing the results across all properties, no 
significant variation in observed error can be noted, as shown in Table 2.3. The aim 
of this study was to investigate if a small number of surface descriptors can be used 
to characterize the distribution of physico-chemical properties of the protein. Thus, 
we decided to allow patches with maximum edge length of nine, as this would prevent 
the splitting of large patches into smaller fractions, resulting in a decrease in number 









Table 2.2. Average Relative Error of Gaussian Fitting for Individual Properties with 








 4 8 12 
El.st. 0.158 0.166 0.169 
H.phobic 0.144 0.166 0.185 
Donor 0.238 0.270 0.299 









Table 2.3: Average Relative Error of Gaussian Fitting for Individual Properties with 
Variation of Maximum Patch Size (Residual Fit). Minimum number of points in patch 




Maximum edge length 
 
 
 5 6 7 8 9 
El.st. 0.141 0.148 0.153 0.158 0.158 
H.phobic 0.138 0.141 0.141 0.143 0.144 
Donor 0.240 0.240 0.238 0.238 0.238 








2.4.2 Characterization of distributions of properties 
We characterized how the different physico-chemical properties are 
distributed on the surface by analysing the size of the patches, and the magnitude and 
widths of the fitted Gaussian functions. Here we considered the results from the 
Residual Fit analysis. 
Figure 2.4 shows that the largest portion of patches are small in size, with a 
maximum number of patches with a size between four and ten (~1-3 Å2) for all 
properties except hydrogen bond donors which adopts a broad maximum at a patch 
size containing about 20 surface points (~5 Å2). The frequency of obtaining large 
patches decreases rapidly with size for electrostatic and hydrogen bond properties, 
however this trend is weaker for hydrophobic properties. Compared to hydrogen bond 
properties, the interaction potential for hydrophobic contacts (equation 2.3) has a 
longer interaction range. Furthermore, the hydrophobic function doesn’t contain any 
directionality information, thus the hydrogen bond patches are more localized and 
consequently smaller in size compared to the hydrophobic patches. Electrostatic 
interactions are dependent on the partial charges, which for formally neutral chemical 
groups are due to differences in electronegativity of bonded atoms. The connected 
atoms in those groups typically have alternating signs of partial charge. On the 
contrary, hydrophobic moieties in the binding site of protein consist of a collection 
of connected atoms. Thus, it is not surprising that hydrophobic surface patches are 

























Figure 2.4. Distribution of number of patches with a specific patch size for 
electrostatic (A, negative, B, positive), C, hydrophobic, D, hydrogen bond donor and 





















Figure 2.5: Distribution of width of Gaussian fit to patches with electrostatic (A, 





























Figure 2.6: Distribution of amplitude of Gaussian fit to patches with electrostatic (A, 















The trend for the distribution of patch sizes for the different physico-chemical 
properties is reproduced in the distribution of the width of the Gaussian function fit 
to the patches (Figure 2.5). Width has been defined as half of the sum of the lengths 
of the principal axes of the Gaussian function. Compared to electrostatic and 
hydrogen-bond properties, hydrophobic patches are on average larger in size and 
consequently Gaussian fits display larger widths. 
Figure 2.6 displays the distribution of amplitudes of the Gaussian fits for the 
various properties. Interestingly, on average the negative electrostatic potential is 
smaller in magnitude than the positive electrostatic potential. This reflects the smaller 
van der Waals radius of partially positive hydrogen atoms compared to partially 
negative nitrogen, oxygen, sulphur or carbon atoms. Thus, surface points on the 
solvent accessible surface are on average closer to positive atoms than to negative 
atoms, which results in stronger positive electrostatic potential compared to negative 
potential. Most hydrogen bonding patches have amplitude of around one or minus one 
consistent with the maximum hydrogen bond strength of one according to equation 
2.2. Hydrogen-bond acceptor patches with amplitude up to two and donor patches 
with amplitude up to three have been identified. Those patches represent surface 
regions that share multiple nearby hydrogen-bonding functional groups of different 










2.4.3 Similarity of binding sites 
We also investigated how similar the identified patches and Gaussian fits were 
for different crystal structures of the same protein.  For this study, we ran the PLSIA 
program on a set of structures for 4 different proteins: Estrogen receptor, CDK2, HIV 
protease, and RARγ.  The estrogen receptor set includes both protein structures with 
bound agonists and antagonists.  We performed a clique detection analysis of the 
distances between centers of the surface patches (see section 2.2.8) for all pairs of 
protein structures. The results were evaluated for pairs of structures of the same 
protein system and different protein systems (Figure 2.7). 
For the RARγ and agonist-bound estrogen receptors, there is clear separation 
between the similarity scores (equation 2.5) for comparisons between structures of 
the same protein system with respect to comparisons to structures of other protein 
systems.  Such a clear separation was not identified for the other protein systems, 
though for CDK2 and HIV protease the intra-protein scores are slightly higher relative 
to the comparisons with the structures of other protein system. For antagonist bound 
estrogen-receptor structures, a separation to comparisons with other protein systems 
is observed but not to comparisons with agonist-bound estrogen structures. This is not 
surprising, as the antagonists bind also to the agonist binding site but their chemical 
structure typically extends to a solvent-exposed moiety. As the used similarity 
measure (Equation 2.5) is normalized to the minimum number of patches in either of 
the two compared protein structures (here the agonist bound structures), the partial 








Figure 2.7: Similarity score (Equation 2.5) for all pairs of protein structures using 
clique detection on the centers of surface patches.  Each column represents all pair -








Analysing each individual protein structure (Figure 2.8) reveals that in all 
cases the average similarity score to any protein structure from the same protein class 
is higher than the corresponding average score to any other protein structure. Thus, 
the analysis still seems to preferentially select members of the same protein class 
against other protein systems, even for CDK2 and HIV protease.  
Visual comparisons of pairs of protein structures of the same protein system, 
reveals that low similarity scores are often associated with conformational changes in 
the binding site (Figure 2.9). The structures of the binding sites of agonist-bound 
estrogen receptors are relatively similar, resulting in comparable locations of the 
Gaussian centers and consequently large similarity scores. In contrary, the CDK2 
system shows significant conformational variation in the binding pocket, which leads 









Figure 2.8: Difference in average similarity score (equation 2.5) between 
comparisons to protein structures within and without the same protein class for all 
protein structures. Positive values correspond to larger similarity among members of 
the same protein class.  Every individual protein structure was more similar to 
members of its protein class (represented by a positive score) than to other protein 








Figure 2.9: Pairwise comparison of Gaussian centers for two protein structures for 
two different protein systems, agonist-bound estrogen receptor (top) and CDK2 
(bottom). Top: Binding site residues for the estrogen receptor structures 1gwr (black) 
and 1gwq (grey) are displayed as lines, the corresponding Gaussian centers are shown 
as small solid spheres (1gwr) and large transparent spheres (1gwq). The binding site 
residues don’t display significant conformational changes, resulting in similar 
positions of Gaussian centers. Bottom: The extended loop regions in 1rej (black) and 
1b38 (grey) show significant conformational differences resulting in poor overlap 
between Gaussian centers of 1rej (small solid spheres) and 1b38 (large transparent 
spheres). Gaussian centers for electrostatic negative patches are colored cyan, positive 







2.5 PLSIA Conclusions 
In this chapter we studied if the physico-chemical properties of the binding site of 
a protein can be accurately represented by surface descriptors modelled by 2-D Gaussian 
functions fitted to surface patches. Properties such as electrostatic and hydrophobic 
properties are accurately fitted using Gaussian functions with an average relative error 
around 15%. Hydrogen bond properties are more localized but display larger errors around 
20-25% compared to other properties. One contribution to this increased error is that 
hydrogen bonds are directional but the vector of directionality of a hydrogen bond donor 
or acceptor doesn’t necessarily point in the direction of the surface normal. Adding a 
directionality term to the Gaussian fit function may reduce the error of fit but increases the 
number of fit variables and consequently the potential of overfitting. 
The type and location of the Gaussian centers is consistent among different structures 
of the same protein system, if no significant conformational changes are observed in the 
binding site upon binding of different ligands. On average, only about six Gaussian 
function descriptors are necessary to model each physico-chemical property important for 
ligand binding. This demonstrates the potential to use 2-D Gaussian functions in surface-
based pseudoreceptors allowing for a significant reduction of number of descriptors in the 
QSAR modeling process. 
***Note: Portions of this chapter previously published in: 
Wilson, GL.; Lill, MA. Towards a realistic representation in surface-based 
pseudoreceptor modelling: a PDB-wide analysis of binding pockets, Molecular 
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CHAPTER 3.  OPTIMIZING SURFACE REPRESENTATIONS OF BINDING 




As mentioned in Chapter 1, there are several major classes of pseudoreceptor 
methods including atom-based, fragment-based and residue-based methods1,2.  One major 
class is surface-based methods, where the pseudoreceptor is represented as a curved 3-D 
surface with physicochemical properties mapped onto it representing protein properties 
important for protein-ligand interactions3-6.  These surfaces are generated in a number of 
ways.  In Receptor Surface Models (RSM), a “shape field” for each ligand is generated that 
represents the molecular volume3-5.  The fields for all ligands are then combined, and an 
iso-level surface is generated based on the combined shape field.  In RAPTOR, an iso-
surface approximating the solvent-accessible surface of the aligned ligand-set is generated6.  
The occupancy of every ligand atom is mapped onto a grid according to a smooth function 
ranging from 1 at the atom center to 0 at its solvent accessible surface. An iso-level surface 
is then generated again, similar to the RSM approach.  Atom-based approaches use similar 
methods to determine where to place the atoms of the pseudoreceptor7-11.  For example, 
FLARM generates a spherical grid around the geometric center of the aligned ligands8.  







a ligand atom. The surface is finally relaxed to allow for a cushion distance of less than 
one Å between ligand and pseudoreceptor.  In WeP11, the marching cube algorithm is used.  
The space surrounding the ligand set is divided into cubes and steric overlap of a methyl 
groups (2.0 Å probe radius) placed on each cube vertex with the ligands is tested.  The 
interacting cube vertices are then used for generating a triangulated surface representing 
the pseudoreceptor.   
Whereas those different schemes aim to empirically reproduce the surface of the 
binding site using ligand information only, to the best of our knowledge, no systematic 
investigation was performed to validate which surface generation process most accurately 
reproduces the surface of the real binding site of experimentally determined protein-ligand 
structures. 
In general, experimental information about the protein structure is not used to 
generate a pseudoreceptor. In this study, however, we will use experimental data to 
optimize the pseudoreceptor method to accurately represent the binding pocket for any 
given protein.  We studied a number of protein-ligand crystal structures for three different 
protein systems and investigated whether the molecular surface of the protein structure can 
be reproduced with iso-surfaces generated from the corresponding co-crystallized ligands. 
Throughout our analysis, we have identified a set of parameters that reliably reproduces 












3.2.1. Protein Surface Generation 
For the protein-surface analysis  35 protein-ligand structures from three protein 
systems were selected from the Protein Data Bank (PDB) (www.rcsb.org)12: 20 cyclin-
dependent kinase 2 (CDK2) structures, 7 estrogen receptor  (ER) structures, and 8 HIV 
protease (HIV-PR) structures. (Table A1)  The crystal structures within each protein system 
were aligned to each other using PyMOL.  The molecular surface of each protein binding 
pocket was then identified using MSRoll in conjunction with our previously described 
refinement algorithm13. (Figure 3.1a) For ER, surface points with a maximum distance of 
4 Å to any ligand atom was used; for CDK2 and HIV-PR this cut-off was set to 5 Å.  The 
lower cut-off for ER was necessary to prevent the inclusion of surface points in our analysis 
that result from cavities other than the binding pocket. 
 
3.2.2. Occupancy Calculation 
The crystal structure ligands were extracted from the aligned PDB structures and 
grouped into five categories: ER, HIV-PR, CDK-20, CDK-10, and CDK-5.  The ER, HIV-
PR, and CDK-20 groups contain all ligands for each respective protein system, while CDK-
10 and CDK-5 are randomly chosen subsets of the CDK-20 group made up of ten and five 
ligands respectively.  A grid around the aligned ligand molecules was constructed using 
the minimum and maximum x-, y- and z-values, (xmin, ymin, zmin) and (xmax, ymax, 
zmax), respectively of any atom of the ligand set plus an additional 10 Å cushion in each 
positive and negative direction.   Grid points were placed starting from (xmin, ymin, zmin) 








Figure 3.1:  Schematic of algorithm: (a) Generation of triangulated protein surface.  Red 
triangles and lines are vertices and edges of triangulated MSRoll surface.  Blue circles 
represent grid points generated in subsequent steps. (b) Occupancy of ligand molecules 
mapped to grid.  Occupancy of ligand 1 (pink) and ligand 2 (green) are calculated on grid 
points.  Occupancy is averaged across all ligands to produce final value (black).  (c) Iso-
surfaces of ligand occupancy are generated.  Occupancy values are interpolated between 
grid points to match a target iso-level.  These vertices are then used to generate an iso-
surface shell of ligand occupancy.  The solid black line represents the 0.1 occupancy iso-
surface, the dashed line the 0.7 occupancy iso-surface. (d) Interpolation of protein surface 
occupancy.  Protein surface points (red triangles) are placed inside the grid generated from 
their corresponding crystal ligands (blue circles).   The ligand occupancy values of these 








The steric occupancy of the ligand atoms were then mapped onto the grid.  These 
occupancy values represented the shared volume there would be between a sphere placed 
on the grid point with the molecular (van der Waal’s) volume of a ligand atom, with a value 
of one representing full overlap, and zero indicating no overlap.  Occupancy was calculated 
with the same function as used in the RAPTOR QSAR package6: 
























              𝑑 < 𝑀   (3.1) 
𝑂 = 0                                                                                                𝑑 ≥ 𝑀 
𝑀 = 𝑟𝑣𝑑𝑊 + 𝑐                                                                                                  
Where O is the occupancy, d is the distance between ligand atom and grid point, and M is 
the maximum radius.  The maximum radius for a ligand atom is defined as the van der 
Waal’s radius rvdW of that atom plus a constant value c.  In this work, four different 
constants were used: c = 1.4 Å, 2.0 Å, 2.5 Å, and 3.0 Å. (Figure 3.2) The 1.4 Å constant 
reflects the solvent accessible surface (SAS) of a ligand, as the occupancy function reaches 
zero at the SAS radius using this constant.  
For every ligand molecule, the occupancy for each atom was computed on all grid 
points within 4 Å plus the van der Waals radius of the atom. (Figure 3.1b) The highest 
atom occupancy for every given grid point was stored as the final occupancy value for the 
ligand molecule.  In the cases of the 1H00 structure for CDK2, there were two ligand 
conformations present, so the occupancy values for the grids of the two conformations were 
averaged to give a final occupancy for that ligand.  The occupancies for all ligand 
molecules within a set were then averaged to produce a final occupancy for each grid point 
















Figure 3.2: Occupancy as function of distance with varied values of c.  Function begins at 
a value of one at zero distance and decays to zero at a distance equal to the sum of the van 
der Waals radius of an atom plus a constant c.  In this graph, the van der Waals radius is 









The occupancy grid was used for the final two steps of the analysis:  comparison 
with the protein surfaces and construction of iso-surface shells.  For a given iso-level, the 
iso-surface was constructed using the marching cubes algorithm14.  First, the occupancy 
grid was searched in a systematic manner, starting with the origin point of the grid (xmin, 
ymin, zmin).  The seven vertices surrounding this point in the positive x, y, and z directions 
were identified and used to generate a cube.  If all eight vertices of the cube have occupancy 
values higher or lower than the target iso-level, the cube was discarded and the next cube 
was searched.  This process continued until the full grid had been searched and all 
occupancy values mapped.  
When a cube had at least one vertex with occupancy higher than the target iso-level 
and at least one vertex with occupancy lower than the target iso-level, it was identified as 
a “surface cube” at a given iso-surface level. The marching cubes algorithm then 
determines the intersection of the target iso-surface with the cube.  This was done by 
interpolating where the edges of the cube intersect with the iso-surface. These intersections 
are then used to determine one or more surface triangles representing the target iso-surface.  
These triangles were then stored, and once all cubes had been searched, combined into a 
single triangulated iso-surface shell of the ligand occupancy. This is illustrated in Figure 
3.1c.  The grid in the figure has been divided into four squares representing cubes of the 3-
D grid, and two example iso-surfaces.  The 0.1 iso-level value iso-surface passes through 
the top two squares, as they have lower vertices greater than 0.1 and upper vertices less 







An iso-surface with target value between 0.35 and 0.65 would pass through all four squares, 
as each has at least one vertex above and one vertex below that value.  
The final process of the algorithm was to compare the known protein surfaces 
generated from the crystal structures with the occupancy grid generated from the co-
crystalized ligands of those structures.  To achieve this, the surface points, generated from 
MSROLL, for each protein structure of a set were placed into the generated occupancy grid 
of the ligands.  The eight grid vertices of the occupancy grid surrounding every surface 
point were identified, and tri-linear interpolation was used to determine the occupancy 
value at the coordinates of the surface point. (Figure 3.1d)  This value represents which 
iso-surface shell of the ligand would pass through each given protein surface point.  This 
process was repeated for every protein structure of a given set.  
Histograms were generated to determine how well an iso-surface a given iso-level 
is able to reproduce the experimental protein surface.  The histograms measure the percent 
of protein surface points that are spatially congruent with the iso-surface at a given iso-
level of occupancy displayed on the x-axis of the graphs.  When discussing the graphs, 
coverage percentage refers to the percent of protein surface points that would be contained 
within an iso-surface shell of a given iso-level.  Cumulative occupancy graphs were 
generated to display the coverage percentage.   
 
3.4 Results 
The primary focus of this study is to derive an optimized algorithm to generate 
pseudoreceptor surfaces that closely mimic the experimental binding pocket surface of 







both a quantitative as well as a qualitative analysis of the results of our algorithm, 
generating the following results for the individual protein systems. 
 
  3.4.1 Estrogen Receptor 
Figure 3.3 shows the histogram results for the surface comparison analysis using 
the four different constants c for the ER protein set.  The results for the 2, 2.5, and 3 Å c-
values show similar profiles. The higher c-value histograms show shifts towards higher 
average occupancy values.  This is due to the fact that once a surface point lies within the 
maximum distance of the occupancy function an increase in the c-value will simply result 
in an occupancy value closer to one.  There are slight differences between these three 
constants:  instead of the single maximum in the histogram using c = 2.0 Å, for c = 3.0 Å 
there is a small additional maximum at lower occupancies.  This feature starts to appear in 
the c = 2.5 Å statistics. This is most likely caused by ligand variation.  One ER ligand is 
significantly different from the rest, with a group occupying a unique region of space.  This 
difference causes a large variation in the protein surfaces, and causes the double maxima, 
as there are two distinct surface profiles.   For c = 1.4 Å, a significantly different profile is 
observed with a small number of points located outside the maximum distance: 
approximately 0.15%.  This means that these points are located more than the c-value plus 
van der Waal’s radius away from any ligand atom.  The width of the histogram peak is also 
very compressed, with 25% of points located between occupancies of 0 and 0.15 with the 

















Figure 3.3: ER occupancy distribution graph with varying values of c in occupancy 
calculation.  Occupancy values are binned in .05 width increments, starting with 0.025 as 
a bin center representing the 0-0.05 bin and increasing to 0.975.  Bins are inclusive on the 
upper limit, exclusive at the lower limit. An additional zero bin is added which includes 








Figure 3.4 shows the cumulative histogram for the ER system.  Of particular interest 
are the occupancy bounds for the majority of the surface points (i.e. finding the ligand iso-
surface shells that would surround the majority of surface points.  For c = 1.4 Å, 93% of 
protein surface points have interpolated occupancies higher than 0.05, and 74.4% higher 
than 0.10.  On the other tail, only 1% of points have occupancies higher than 0.65, 6% 
higher than 0.45, and 13% higher than 0.35.  Together, this means 80% of surface points 
are located between 0.05 and 0.35 occupancy, 90% between 0.05 and 0.55 and 99% 
between 0 and 0.65.  For the other values of c, the occupancy iso-levels with the same 
percent coverage increase with c-value.  This occurs through all coverage percentages, 
increasing with greater iso-level values, leading to an increase in the difference of iso-level 
values between any two coverage percentages.  For example, 94% of points have higher 
occupancies than 0.1, 0.15, and 0.2 for the 2.0, 2.5, and 3.0 Å constant values, respectively.  
The 5% coverage iso-levels are for these runs: 0.6, 0.7 and 0.75.  So the total separation 
for the iso-surface shells containing between them 90% of protein surface points increases 
from 0.5 occupancy difference for 1.4 Å to 0.55 for the 3.0 Å run.  The 99% separations 


















Figure 3.4: ER accumulation graph with varying c-values in occupancy function.  Y-axis 
is percent of total protein surface points with iso-level of less than or equal to the x-axis 









The results for HIV-PR are shown in Figure 3.5.  The results for this system follow 
similar trends to the ER system.  The distribution profile for c = 1.4 Å is significantly 
different from the other three c-values.  New profile features start developing when c = 2.0 
Å, and these features develop fully in the 2.5 Å and 3.0 Å runs, which show very similar 
profiles.  A major difference between the results for HIV-PR as compared to ER is that it 
is not until c = 3.0 Å that all surface points have a higher than 0 occupancy.  This is partly 
expected, as the distance cut-off for protein surface points is 1 Å larger for the HIV-PR and 
CDK systems.  While the percentage of uncovered surface points is relatively high, 5%, 
for c= 1.4 Å, it decreases to 1% and then to 0.08% for c = 2.0 Å and c = 2.5 Å.  The bimodal 
motif that was partly evident in the ER set is much more pronounced in the HIV-PR set 
when c= 2.5 and 3.0 Å, with a swift increase at low occupancies that plateaus for a 
significant range of occupancies, and then increases to a maximum followed by a decrease, 
as seen in Figure 3.5.  
The accumulation results for the HIV-PR set are shown in Figure 3.6 and Table A5.  
For c= 1.4 Å a significant fraction of points have low occupancies.  20% of protein surface 
points have occupancy less than 0.05.  99% of points have occupancy lower than 0.55, 95% 
lower than 0.45, and 90% lower than 0.35.  For c = 2.0 Å, 99% of points have occupancy 


















Figure 3.5: HIV-PR occupancy distribution graph with varying values of c in occupancy 
calculation.  Occupancy values are binned in .05 width increments, starting with 0.025 as 
a bin center representing the 0-0.05 bin and increasing to 0.975.  Bins are inclusive on the 
upper limit, exclusive at the lower limit. An additional zero bin is added which includes 

















Figure 3.6: HIV-PR accumulation graph with varying c-values in occupancy function.  Y-
axis is percent of total protein surface points with iso-level of less than or equal to the x-









In this work, three different sets of CDK2 ligands were used to produce occupancy 
data: CDK-20, CDK-10, and CDK-5.  CDK-10 is a subset of CDK-20 and CDK-5 is a 
subset of CDK-10.  In the analysis stage, however, all twenty protein structures were used 
for all three ligands sets.  This was done to determine how well the iso-surface shells from 
a smaller ligand set correspond to the larger ensemble of protein structure. Figure 3.7 and 
Tables A6-A11 show the results for the individual sets. (Occupancy accumulation graphs 
for CDK are not shown)  Whereas the total range of occupancy values of the protein surface 
points is similar in all sets compared to the HIV-PR and ER system, there is a notable shift 
in the distribution of occupancy values towards higher median occupancies for all c-values 
higher than 1.4 Å.  This shift in average occupancy increases with the size of CDK set, 




























Figure 3.7: CDK occupancy distribution graphs with varying values of c in occupancy 
calculation for all three CDK systems.  Occupancy values are binned in .05 width 
increments, starting with 0.025 as a bin center representing the 0-0.05 bin and increasing 
to 0.975.  Bins are inclusive on the upper limit, exclusive at the lower limit. An additional 
zero bin is added which includes the fraction of protein surface points with no mapped 










Looking at the four different c-values across all three sets, there are a number of 
similar trends.  First, the larger the ligand set, the higher the maximum.  Second, the smaller 
the ligand sets the more surface points are located at the extreme occupancies: more points 
with very low occupancy and more points with very high occupancy.  For the high 
occupancy points, this is due to the averaging occurring in the occupancy calculation.  As 
more ligands are included, with spatial and chemical diversity, the high occupancy iso-
surface shells decrease in volume.  In addition, at very high iso-levels, approximately 0.9, 
the algorithm fails to build a full continuous shell.  This is due to the averaging process 
across diverse ligands leading to low maximum occupancies.  For example, if a set was 
comprised of two non-overlapping ligands, the maximum possible occupancy would be 0.5 
due to the averaging process.  The reason for the higher number of very low occupancy 
points is the inverse of this process.  As long as a surface point falls within the cut-off 
distance of a single ligand atom, it receives a non-zero occupancy value, even if the 
averaging process makes it very small.  This process shifts points to lower occupancies 
overall, which results in the increasing maxima, which are located at low occupancy values 
in all three CDK sets.  
 
3.4.4 Iso-surface Shells 
While looking at the previous histograms provides information on how many 
protein surfaces points are covered by a given iso-surface shell, it does not provide the 
whole story on the quality of the fit.  For example, a 50 Å sphere centered on a ligand set 
would likely provide 100% coverage, while being of poor use in pseudoreceptor modeling.  







inspection.  Similar to the previous section, we wanted to investigate the effect of changing 
the distance constant c, the number of ligands used in shell generation, and target iso-level 
on the overall shape and size of the iso-surface.  When referring to these figures, exterior 
refers to the space that is located outside of the protein surface when viewed from the ligand 
center; interior refers to the space inside the protein surface, respectively.  The transition 
region is the 3-D space where the protein surface points are located. (Figure 3.8) 
Figure 3.9 shows the 0.05 iso-surface shell of the HIV-PR system at the four 
different c-values.  The overall shape of the shells is similar for each c-value, the primary 
change being the spatial extension of the shell.  Figure 3.13 also demonstrates how closely 
the shells match the protein surface.  Using c = 1.4 Å, the majority of the shell is located 
slightly to the exterior of the protein surface points, but is in the transition region in some 
portions.  For c = 3.0 Å, even though the iso-surface shell is located almost exclusively to 
the exterior, the shell is overall significantly larger than the protein surface.  The 
intermediate c-value iso-surface shells fall between these two extremes, with decreasing 









Figure 3.8: Definition of terms for discussion of iso-surface shells.  Red triangles and lines 
represent individual protein surfaces.  Black lines divide space into three regions: exterior, 
transition region, and interior.  Interior refers to the region of space that is enclosed by all 
protein surfaces, corresponding to the intersection of all protein binding pockets.  The 
transition region refers to the 3-D space where the varying protein surfaces are located.  
The exterior is refers to the region of space that would be filled by the protein or bulk 









Figure 3.9: 0.05 Iso-level shells for HIV-PR with varying c-values: (a) 1.4, (b) 2.0, (c) 2.5, 
(d) 3.0.  The iso-surfaces are generated using an iso-level of 0.05.  Increasing c-value 
results in an expansion of the shells.  All sub-figures focus on the same region of the HIV-
PR binding pocket showing the larger shells including previously excluded protein surface 








The effect of changing the number of ligands in the CDK systems is shown in 
Figure 3.10.  The shells shown represent the 0.05 iso-surface with c = 2.5 Å.  Overall, the 
three iso-surface shells are very similar.  No shell is consistently larger than any of the 
others, though there are regions where each shell is largest.  However, as the size of the 
ligand set increases, the curvature of the iso-surface shells becomes more refined, creating 
a slightly more complex surface.  This consistency is desirable, as it indicates that a small 
ligand set can generate a pseudoreceptor that could be applicable to a larger set of ligands 
as long as they cover similar space in the binding pocket.  This is the case for the CDK 
system we studied where the ligands of the CDK-5 set cover roughly the same 3-D space 
when aligned as the full CDK-20 set.    
Figure 3.11 shows the iso-surfaces of the ER system at varying iso-levels with c = 
3.0 Å.  The 0.05 shell encompasses nearly all of the protein surface points and follows the 
contours of the protein surface.  As the iso-level value increases, the encompassed volume 
of the shells decreases.  This decrease is most pronounced in the region indicated by the 
red arrow in Figure 3.11b.  This region is occupied by a single protein-ligand complex 
(2P15), and receives a very low average occupancy value, and the 0.25 iso-surface shell 
does not contain this region.  The 0.5 iso-surface shell is mainly located in the transition 
region of the protein surface points.  At high iso-levels, such as 0.75, the shell is almost 



























Figure 3.10: 0.05 Iso-level shells of CDK sets with c-value of 2.5 and iso-level of 0.05.  
(a) Paired shells for CDK-5 (red) and CDK-10 (blue), (b) CDK-5 and CDK-20 (green), (c) 
CDK-10 and CDK -20.  While slight variations exist between all three shells, the overall 









Figure 3.11: Iso-surface shells of estrogen with c=3.0.  Iso-levels are (a) 0.05, (b) 0.25, 
(c) 0.5, (d) O.75.  The size and shape of the iso-surface shell varies significantly with 
change in iso-level.  Most notable is the change between the 0.05 shell and the 0.25 shell 
in the region indicated by the red arrow in sub-figure B.  The protein surface points in 
this region come from a single protein structure, giving the region a very low average 
occupancy even where the ligand for that structure is located.  This causes a dramatic 
difference between the 0.05 shell, which includes the full region, and the 0.25 shell which 








As previously mentioned, the focus of our research was to determine a means of 
producing a pseudoreceptor iso-surface that corresponds to the protein-ligand interaction 
surfaces present in PDB crystal structures.  To achieve this goal, we first investigated how 
well the composite solvent-accessible surface (SAS) of a ligand set reproduces the protein 
surfaces, as the SAS is used in a number of pseudoreceptor generation methods.  We 
approximate this surface by setting c=1.4 Å.  At this value, the occupancy function decays 
to zero when a grid point is 1.4 Å plus van der Waals radius away from a given ligand atom.  
Therefore, any grid point with occupancy greater than zero would be within the typical 
SAS, while grid points with zero occupancy are outside the SAS. The SAS covers the 
majority of protein surface points.  However, with the exception of the ER system, there 
remained a small portion of surface points not contained within the SAS, with a minimum 
coverage of 92% for the CDK-5 set. In addition, from visual inspection, the SAS iso-
surface shells with low (<0.05) iso-levels, are located in close proximity to the protein 
surface.  Conversely, increasing the c-value to 3.0 Å ensures nearly complete (>99%) 
coverage, but the iso-surface shells included portions in 3-D space that would overlap with 
the protein.   
In order to create an accurate pseudoreceptor surface model, we need to find a 
balance between achieving the maximum possible coverage of protein surface points and 
smoothly approximating the protein surfaces without significant overlap with the protein.  
Also, from visual inspection, coverage percentage may be misleading in certain cases.  
When a protein binding pocket is solvent exposed, it is possible for surface points that are 







opposing geometries of the protein binding pocket which are concave and the generated 
iso-surface which is convex, slightly lower coverage percentages are observed. This 
underestimation must be considered in evaluating the results of the algorithm.  From our 
results, we would recommend a c-value of less than or equal to 2.0 Å, as higher c values 
produce shells that are significantly larger than the protein surfaces at low iso-levels.  For 
these c-values, we recommend an iso-level target of <0.05, as these parameters result in 
iso-surface shells that cover approximately 95% of protein surface points, while smoothly 

















Figure 3.12:  Scheme for coverage percentage of solvent exposed ligand binding pockets.  
Red triangles and line represent the protein surface of a single protein-ligand crystal 
structure.  Due to curvature where the pocket is solvent exposed, certain protein surface 
are included within the distance cut-off of the algorithm that do not fall within the convex 








While the previous parameters for c and iso-level are useful in determining an iso-
surface shell that encompasses the full combined protein surface, this shell fails to address 
a number of issues.  First, ligand diversity can vastly increase the size of an iso-surface 
shell constructed from a low iso-level target, as seen in the ER system, where there is a 
vast difference between the 0.05 shell and the 0.25 shell due to a single ligand having a 
pose which occupies a different region of the binding pocket compared to all other ligands.  
In addition, the surfaces of the individual proteins vary significantly due to protein 
flexibility, resulting in a wide range of mapped occupancies (>0.5 iso-level difference 
range for 95% of protein surface points).  With respect to pseudoreceptor modeling, this 
means while the low iso-level iso-surface shell represents the outermost surface to all 
ligands, it does not fully replicate the surface with which an “averaged” ligand would 
interact, especially if the ligand set is diverse.  This averaged surface would be represented 
by an iso-surface shell closer to interior of the protein surface points, inside the transition 
region.  As seen in Figure 3.11, in the ER system the iso-level that corresponds to this 
region is in the range of 0.5-0.6. 
It is also important to note, that while the suggested parameters represent general 
starting points, they will not be ideal for all protein ligand systems.  In just the three systems 
considered in this study, there are significant differences in the occupancy profiles of the 
protein surface points.  The flexibility of the protein and the diversity of the ligand set play 
important roles in determining the ideal parameter set.  A rigid system would lead to a 
lower ideal c-value, as seen in the ER system, where even with c=1.4, less than 0.1% of 
protein surface points do not have an occupancy value.  Increasing ligand diversity leads 







CDK-20 set, it is impossible to create an iso-surface shell with iso-level greater than around 
0.7, as the surface becomes discontinuous due to ligand diversity and the averaging process 
in the occupancy calculation 
These individual factors lead to a number of final conclusions.  First, it appears to 
be unlikely for a single pseudoreceptor surface to fully and accurately replicate the 
individual protein binding pockets for a diverse ligand set.  A low iso-level produces an 
iso-surface shell that contains the surfaces for all ligands, but can vary significantly from 
individual protein surfaces where there is diversity in a ligand set.  Higher iso-level iso-
surface shells more closely reproduce the surface that an “average” ligand would see, but 
lose the unique features of more diverse ligands.  To address the drawbacks of the 
individual surfaces, it may be advantageous to use an ensemble of pseudoreceptor surfaces.  
RAPTOR implements a version of this with its dual-shell model6.  In this model, two iso-
surfaces are built using the most affine ligand as the basis for the inner shell and all ligands 
for the outer shell.  We propose a similar solution, utilizing multiple shells of varied iso-
levels: higher iso-level shells would represent the conserved portions of the ligand, and low 
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CHAPTER 4. INTEGRATED STRUCURE AND LIGAND-BASED METHOD FOR 
THE PREDICTION OF SITES OF METABOLISM OF CYTOCHROME P450 
ISOZYMES. 
***Note: This chapter was performed in collaboration with Dr. Laura Kingsley and 
Morgan Essex.  Dr. Kingsley and Ms. Essex were responsible for the method 
development of the MD simulations, ensemble selection and generation, and docking, 
and performed these studies on CYP2C9.  Gregory Wilson was responsible for the QSAR 
development and studies on CYP2C9.  He also performed all studies for the remaining 
CYP isozymes and is responsible for webserver development.  Portions of this chapter 
previously published in:  
Kingsley, LJ.; Wilson, GL.; Essex, ME.; Lill, MA. Combining Structure- and Ligand-
Based Approaches to Improve Site of Metabolism Prediction in CYP2C9 Substrates. 
Pharm. Res., 2015, 32, 986-1001. 
4.1 Introduction 
As discussed in Chapter 1, our group has previously implemented a method that 
combined ensemble docking and NAT reactivity scores in an integrated structure and 
ligand-based tool for the prediction of CYP SoMs.  The success of this approach was in 
part attributed to the inclusion of critical binding site conformations during docking via 
the use of a protein ensemble which led to a ~10% improvement in identifying reactive 
ligand poses  as compared to docking to the crystal structure alone1.   
While the inclusion of protein flexibility using an ensemble of protein structures 
improved the generation of docking poses that were consistent with the experimentally 
known SoM, the number and diversity of false poses also increased. This increase in 







and was  thought to be the primary cause of the reduced prediction accuracy of docking 
observed in the top-1, top-2 and top-3 positions1. The poor docking performance in the 
ensemble is likely one of the key reasons that the improvement in SoM prediction 
accuracy in the ensemble was only modest compared to using only the crystal structure1. 
Based on our previous findings, we have developed a revised methodology to better 
incorporate protein flexibility and to better rank predicted poses in CYP2C9. The two 
main methodological improvements compared to our previous approach are a pre-
filtering process to reduce the size of the protein ensemble used in docking and the 
implementation of pseudoreceptor modeling to accurately rank the binding poses relevant 
for SoM prediction. Compared to the existing methods cited above, our approach differs 
in method by which the data from docking and SMARTCyp2 are combined, namely a 
modified pseudoreceptor scheme. To the best of our knowledge, this is the first attempt to 
directly incorporate SMARTCyp reactivity data into a pseudoreceptor model that is based 
on structural protein and ligand data to predict SoMs in CYP2C9.  
A schematic of the revised procedure is shown in Figure 4.1. As with our previous 
model, both structure- and ligand-based principles were used in the current scheme; 
SMARTCyp, a successor of the NAT model was used to predict reactivity scores for each 
atom and ensemble docking was used to incorporate structural features of CYP2C9. We 
compared predictions in the crystal structure alone to predictions in a “pseudo-apo” 
ensemble which was selected based on a pre-filtering step used to isolate structures 
relevant for ligand binding. We found that incorporating “pseudo-apo” simulations 
increased the conformational space covered by the binding pocket allowing for successful 







where less than 65% of the ligands tested could be successfully docked. In this study, as 
with our previous study, we noticed that the scoring function used in docking did not 
always accurately predict the correct binding poses. Due to the difficulty of accurately 
ranking poses using the docking scoring function, we introduced a pseudoreceptor model 
to differentiate between poses.  Using the poses generated by docking and the reactivity 
scores generated by SMARTCyp, we produced a dataset suitable for pseudoreceptor 
modeling. A modified, in-house version of the RAPTOR3 pseudoreceptor QSAR suite 
was used to develop a pseudo-receptor model to identify docking poses that correctly 
predict SoMs in our CYP2C9 ligand data set. With this approach we were able to 
significantly improve SoM prediction in the CYP2C9 ligand data set tested. Using a 
combination of docking to the pseudo-apo ensemble, SMARTCyp, and pseudoreceptor 
we were able to accurately predict the SoM in 96% of ligands within the top-2 positions.   
Afterwards, we extended this method to eight additional CYP isozymes and 
obtained similar results.  These isozymes are responsible for metabolism of significant 
percentages of all drugs: 1A2 (15%), 2A6 (3%), 2B6 (8%), 2C8 (8%), 2C19 (12%), 2-D6 



















Figure 4.1: SoM prediction using a combination of structure- and ligand- based approaches. 
Using both atom reactivity data from SMARTCyp and structural data from docking, we 
generated a set of active (true SoM is within 4Å of the reactive oxygen) and decoy poses. 
A subset of these poses was used to train a pseudo-receptor QSAR model which was then 









4.2.1 CYP2C9 Ligand Library Preparation 
A set of 73 structurally diverse CYP2C9 substrates with known SoMs were used 
for this study (Table A12). The compounds were based on those used by Danielson et. 
al(20), which were taken from the literature5 and the University of Washington Metabolism 
and Transporter Drug Interaction database© (www.druginteractioninfo.org). All possible 
stereoisomers (in case that stereochemistry was not defined for the structure) and relevant 
protonation states were considered as unique chemical structures resulting in 139 total 




SMARTCyp2 is a reactivity model that predicts the reactivity at C, S, N, and P 
positions in a given ligand based on a series of over 40 rules derived from quantum 
calculations. SMARTCyp 2.4.2 was used to predict likely SoMs based on reactivity 
energies and atom accessibility in each of the 139 total ligand structures. The atoms of each 
ligand were then ranked according to the predicted abstraction energy, also referred to as 
the SMARTCyp score. In cases where one or more ligand variants existed, for instance two 
possible protonation states of the same ligand, the best (lowest) overall score was selected 
for each atom. The percentage of correctly predicted SoMs in the top-1, top-2, and top-3 
positions were calculated using the experimentally known SoMs. In cases where a given 
substrate had more than one known SoM, only the highest predicted SoM was considered. 







4.2.3. Static Crystal Docking 
  The 1R9O crystal structure of CYP2C9 was used for the static docking studies. 
The co-crystalized ligands, flurbiprofen and glycerol, along with all crystal waters were 
removed. The crystallized heme (deoxygenated) was replaced by an oxygenated heme. 
Protonation and tautomer states of histidine and rotamer states of asparagine, glutamine 
and histidine were assigned using Reduce6. The ligand library was prepared for docking 
using the PyMol plugin developed by Danielson et.al7.  
 
4.2.3.1 Autodock Vina 
 Ligands were docked using AutoDock Vina (Vina). The docking volume was 
defined using our PyMol plugin. The selected docking cuboid was roughly 20Å on each 
side and included the active face of the heme and surrounding residues that could be 
relevant for binding. Default values were used for all docking parameters in Vina. For each 
unique ligand, 10 total docking poses were generated and 5kcal/mol was chosen as the 
maximum energy difference allowed between the best and any other reported docking pose.  
 
4.2.3.2. Ranking 
Docking success was evaluated based on the distance between the known SoM and 
the reactive oxygen of the heme moiety. Because docking to multiple similar protein 
structures can result in redundancy of several ligand poses, the poses were clustered using 
k-medoid clustering. K was iteratively adjusted such that the maximum RMSD between 
any two poses and the cluster center was less than 1.0Å. The pose with the best (lowest) 







Next, docking poses of all protonation states and stereoisomers of a given ligand 
were pooled resulting in a single set of poses for each ligand containing all protonation and 
tautomeric states of the ligand. The combined poses were then ranked according to the 
docking score. If two poses had the same docking score, both would share the same rank, 
but the rank immediately following would reflect the inclusion of multiple poses. For 
instance assuming two poses had the same score and were ranked first, the next compound 
would be ranked in the third position to account for the two ligands that had been previously 
ranked higher.  
A distance of 4.0Å or less between any heavy atom and the reactive oxygen was 
considered to be potentially reactive. Poses that did not have a heavy atom within 4.0Å of 
the reactive oxygen were omitted from the ranking scheme.  
 Next, each atom was assigned the best Vina docking score attained by any pose 
wherein the atom was within 4.0Å of the oxygen on the heme. The atoms were then ranked 
according to the assigned score and the percentage of accurately predicted SoMs that 
occurred in the top-1, top-2 and top-3 positions was calculated.  In addition to determining 
the accuracy of SoM predictions in the top-3 positions, the overall docking success was 
determined for docking to the crystal structure and the ensemble. The overall docking 
success is defined as the percentage of ligands that could be successfully docked regardless 
of ranking. In other words, the overall docking success is a measure of how well the pose 










4.2.4 Ensemble Generation 
4.2.4.1 MD Simulations 
An MD simulation of the pseudo-apo structure of CYP2C9 was used in the 
ensemble generation process. To generate the initial protein structure the ligand was 
removed from the CYP2C9 crystal structure, 1R9O.   
The MD simulation was performed using Gromacs-4.5.58,9 and the Amber03 force 
field. The input structure was prepared using Reduce6 to identify the proper rotamer, 
tautomer, and protonation states of histidine, and the proper rotamer states of asparagine 
and glutamine. The heme parameters were extracted from the literature10. We opted to use 
an oxygenated heme model because the oxygen may be critical for the docking of certain 
ligands. Gromacs was used to solvate the system in an octagonal water box of SPC216 
waters and 6 chlorine ions were added to neutralize the system. The box size was selected 
to guarantee a minimum distance of 15Å between solute and box edge.  
The steepest descent method and particle mesh Ewald (PME) summation with a 
grid size of 0.12nm was used to carry out 1000 steps of energy minimization.  To compute 
van der Waals interactions a switching function was applied between 1.0nm and the cut-
off of 1.4nm. The LINCS algorithm11 was used to constrain bonds containing hydrogen 
atoms. Next the hydrogen bond network of the surrounding waters was established using a 
200ps MD simulation in which all but the waters were restrained. Simulations were 
performed at 300K using PME, Berendsen thermostat, and Parrinello-Rahman pressure 
coupling. The integration time step was 2fs. Finally a 400ps equilibration run was 








4.2.4.2. Ensemble Generation and Refinement 
The initial ensemble was generated by extracting frames every 100ps from the 
pseudo-apo production run. The initial ensemble was then refined using a docking-based 
filtering process resulting in a 6 member ensemble. From the 73 ligands used in this study, 
14 structurally diverse ligands (denoted in Table A12) were manually selected for 
ensemble refinement. These 14 ligands were docked to all members of the 100-member 
ensemble using AutoDock Vina, as described above. Ligand variants were combined to 
give a single set of poses for each ligand as previously described.  
To determine which protein structures were able to best dock the 14-ligand training 
set, a fitness score was calculated for each protein structure as follows: 













5;         𝑟𝑎𝑛𝑘 = 1
4;  2 < 𝑟𝑎𝑛𝑘 < 4
3;  4 < 𝑟𝑎𝑛𝑘 < 6
2; 6 < 𝑟𝑎𝑛𝑘 < 10





   (4.1) 
Where wi is one over the number of protein structures to which the ligand i was successfully 
docked and fi represents an assigned value based on the docking rank. Poses that were not 
successfully docked (e.g. did not have the known SoM within 4Å of the reactive oxygen) 
were given a score of 0, while those that were successfully docked were given a score 
between 1 and 5, based on the rank of the pose.  The factor wi guarantees that protein 
structures are more likely selected for the refined ensemble that allow the successful 
docking of ligands that are difficult to dock.  For example, assume that two ligands A and 
B dock successfully to protein structure S. Assume ligand B is successfully docked to 49 
other protein structures (out of 100 structures in the initial ensemble) and ligand A is only 







ligand A and structurally similar ligands, it should gain a high fitness value and be more 
likely to be included in the refined ensemble. This is achieved by the introduction of the 
weight (wi) which will be 1.0 (1/1) for ligand A but only 0.02 (1/50) for ligand B. 
The protein structures from the ensemble were then ranked by fitness. We found 
that 13 out of 14 ligands could be successfully docked to at least one of the top-5 ranked 
protein structures. The remaining ligand, 2-oxoquazepam, was not successfully docked 
until the 34th ranked protein structure. Based on our previous findings that the inclusion of 
multiple protein conformations can be problematic for the docking scoring function, we 
felt that including 34 structures would be detrimental to the model. We tested the top-4, 
top-6, top-8, and top-10 protein structures on the entire ligand data set (data not shown) 
and found that selecting the top-6 structures achieved optimal template diversity. 
 
4.2.5. Ensemble Docking 
All 139 ligand structures were docked to the 6-member protein ensemble. Ensemble 
docking was performed in a similar fashion as to the static crystal docking described above. 
Again, all ligand variants from all ensemble members were pooled to produce a single set 
of poses for each ligand, the resultant poses were clustered and the cluster member with 
the highest docking score was selected.  
 
4.2.6. Ranking 
 As with the static crystal docking, the atoms of each ligand were ranked according 







percentage of successfully predicted SoMs in the top-1, top-2 and top-3 positions were 
calculated as well as the overall docking success, as described above.  
 
4.2.7. SMARTCyp + Docking 
In an attempt to improve SoM ranking in the top-1, top-2, and top-3 positions, we 
combined SMARTCyp reactivity predictions with the docking results. A single combined 
score (CS) was calculated for each atom of a given ligand using the following function: 
𝐶𝑆 = 𝑅𝑖 + 𝛾𝑆𝑖          (4.2) 
where Ri is the atom’s SMARTCyp reactivity score (usually ranging from about 50 (best) 
to 100(worst)) and Si is the docking score from the highest ranked pose where the atom i 
was within the 4.0Å cutoff from the oxygen of the heme (usually ranging from about -12 
(best) to -6 (worst)). Gamma (γ) is a weighting factor between 0 and 10, and is used to 
adjust the contribution of the docking score (Si) to the total combined score (CS). In order 
to be further considered in the CS scheme, an atom had to have both a docking score and a 
SMARTCyp score, otherwise the atom was omitted as a potential SoM. 
Gamma was optimized using a subset of ligands (denoted in Table A12) and the following 
fitness function: 
𝑓𝑖𝑡𝑛𝑒𝑠𝑠 = (%𝑡𝑜𝑝1) + 0.5(%𝑡𝑜𝑝2) + 0.25(%𝑡𝑜𝑝3)    (4.3) 
Where %top1, %top2, and %top3, reflect the percentage of accurately predicted SoMs in 
the top-1, top-2 and top-3 positions, respectively.  Gamma was initially set to 0 and was 
iteratively increased by 0.5 to a maximum of 100. The gamma value that maximized the 







For each ligand, atoms were ranked by CS value. As with the docking scores, atoms 
with equivalent CS values were ranked at the same position, but the next position reflected 
the inclusion of multiple atoms at the previous position. The percentage of correctly 
identified SoMs in the top-1, top-2 and top-3 ranked atoms was calculated for the x-ray 
crystal structure alone and the pseudo-apo ensemble.   
 
4.2.8. SMARTCyp+ Docking+ QSAR 
In an attempt to further improve SoM prediction results we implemented a modified 
QSAR scheme to evaluate and re-rank docking poses. The SMARTCyp score and free 
energy of binding were combined into the fitness functions used for deriving the QSAR 
model.  
                                                                                                                                                                           
4.2.8.1 Dataset Preparation and Selection 
As described previously, SMARTCyp assigns reactivity scores to all ligand atoms, 
with the lowest score representing the predicted SoM.  When combining the SMARTCyp 
reactivity approach with docking, the SoM predictions can be re-ranked by including only 
those atoms within a reactive distance of the oxygen atom of the heme.  The main limitation 
of this approach is the accuracy of the docking scoring function. Often poses are found in 
which the true SoM is within the cutoff distance (active poses), but these poses may be 
amongst the worst ranked by the scoring function. This problem intensifies as more poses 
are introduced using ensemble docking. To overcome the limitations of docking scoring 







statistical model to differentiate poses that are consistent with the experimentally known 
SoM from those which are not. 
The clustered docking poses were used as input for the QSAR model (Figure 4.2a). 
The poses were first separated into active poses and decoy poses (Figure 4.2b). An active 
pose was defined as a pose in which the known SoM was docked within 4Å of the oxygen 
on the heme and had the known SoM within the top-3 ranked SMARTCyp scores for those 
atoms within 4Å of the heme oxygen atom. The active poses were further classified by 
whether the known SoM had the first, second, or third best SMARTCyp score (Figure 4.2c).  
A decoy pose was defined as any pose that was docked with at least one atom within 4Å 





























Figure 4.2:  Scheme of QSAR modeling process.  First the poses generated by docking 
(a) were separated into active and decoy poses and the actives subcategorized into Top 1, 
Top 2, and Top 3 actives(b).  A driving force (DF) was then assigned to each pose (c) and 
the RAPTOR package was used to generate a QSAR model(d).  After the QSAR training, 
all poses for a ligand are sorted by the QSAR score (e) and atom scores are assigned to 
the top three SMARTCyp atoms for each pose.  Atoms are then ranked by the final score 







4.2.8.2. Test and Training Selection 
  A random set of nineteen ligands was selected as the initial test set for the QSAR 
simulations and the remaining ligands were assigned to the training set.  The value of 
nineteen was chosen as this represented approximately one-quarter of the available ligands 
for QSAR modelling.  The test set was then manually curated to ensure that it covered the 
chemical space of the training set.  During this evaluation, four of the test ligands were 
moved to the training set, and an equal number of ligands were moved to the test set to 
retain the overall 3:1 training to test ratio.  Two of the ligands that were moved into the 
training set had unique ring structures not found in any other ligand in the data set, a third 
ligand had a unique long carbon chain, and the final ligand was the smallest compound in 
the data set.  These unique features cause the ligands to be unsuitable for the test set.  This 
test set was then used for all remaining QSAR simulations. The final training and test sets 
are noted in the “Data Set” column of Table A12.  
As discussed earlier, active poses are further classified based on the rank of the 
SoM using the SMARTCyp score. Thus, for many ligands there are binding poses in which 
the SoM is ranked as most reactive atom (i.e. other more reactive atoms are not within 4Å 
of the catalytic center) and other poses where the SoM is ranked lower (e.g. as top-2 or top-
3) because in addition to the try SoM, other more reactive atoms also fall within 4Å of the 
reactive oxygen. In a strict sense, the later poses disagree with the experimental SoM data 
and would add noise to the QSAR training process. Thus, during QSAR model training 
only the active poses with the highest ranked SoM based on the SMARTCyp score were 
used as active poses. All other active poses, however, were moved into the final prediction 







prediction set was used for final evaluation of SoM prediction quality using our optimized 
QSAR model (Figure 4.1, last step).  
 
4.2.8.3 Inclusion of SMARTCyp reaction scores 
To directly incorporate the SMARTCyp scores into the QSAR model, the RAPTOR 
package was modified.  The original version of RAPTOR uses hydrogen-bond interactions 
and hydrophobic contacts between the ligands and the pseudo-receptor generated by 
RAPTOR to predict binding affinities. In the modified version of RAPTOR, the 
SMARTCyp score was provided as an additional contribution to the overall predicted score. 
Thus, the QSAR score Qscore was computed by the sum of hydrogen-bond interactions 
ΔGHBond, hydrophobic contacts ΔGHPhob and SMARTCyp score SSMARTCyp: 
𝑄𝑠𝑐𝑜𝑟𝑒 = ∆𝐺𝐻𝐵𝑜𝑛𝑑 + ∆𝐺𝐻𝑃ℎ𝑜𝑏 + 0.1 ∙ 𝑆𝑆𝑀𝐴𝑅𝑇𝐶𝑦𝑝      (4.4) 
SMARTCyp scores were assigned to every pose as 1/10th of the original value to 
scale the reactivity scores to the same order of magnitude as the other two contributions to 
the Qscore within the RAPTOR models.  For active poses, the SMARTCyp score of the 
known SoM was used.  For decoys, the lowest SMARTCyp score of any atom within 4.0Å 
of the oxygen atom of the heme was used.  
Also, the input to the QSAR method was adjusted (Figure 4.2b).  Typically, all 
poses for a given ligand are treated as alternative conformations of the same ligand and the 
experimental affinity value is used during the QSAR modeling process for every 
conformation.   For our method, we grouped active and decoy poses separately.  In addition, 
instead of binding affinities, the active poses were assigned a negative score, while the 








between these scores as a “driving force.”  The goal of this driving force is to identify the 
physicochemical features in the QSAR model that allows discrimination between active 
and decoy poses due to differences in protein-ligand interactions.   
In order to determine the optimal driving force, we ran multiple RAPTOR 
simulations with different driving forces.  We ran simulations with both a fixed driving 
force for all active poses, and simulations with a variable driving force for the actives.  For 
the variable driving force simulations, the top-1 actives poses are assigned a value of X-Y, 
top-2 poses  are scored as X, and top-3 poses are scored as X+Y where X and Y are real 
floating point values ranging from -5 to -2 and Y ranging from -1.5 to -0.5.  Using variable 
weights for top-1, top-2 and top-3 poses improved the performance of the QSAR model 
compared to assigning identical weights to all actives. Many of the driving force weights 
generated QSAR models with similar quality.  Therefore, we chose a set of weights in the 
middle of our testing range, i.e. an X value of -3 and a Y value of 1, with the decoy set 
being assigned a value of zero.  This setting had the best performance by a slight margin. 
 
4.2.8.4 QSAR Modeling 
 The modified RAPTOR program was used to generate a pseudo-receptor QSAR 
model for CYP2C9 with all remaining parameters set to their default values.  Five 
individual models, run with the fast search mode, a coupling factor of 0.5 and sharpness 











4.2.8.5 Analysis of QSAR Results 
Typically, pseudo-receptor models are used to predict the binding affinity of a 
ligand.  RAPTOR, in addition to providing an overall prediction of the affinity of the ligand, 
predicts the binding energy for each conformation of a ligand.  In this study, those 
conformations are the individual docking poses for a ligand.  However, here the predicted 
score does not provide an estimate of the binding affinity but yields a likelihood score for 
each conformation to be the pose predicted to have the known SoM within 4 Å of the 
catalytic center. To evaluate the success of our model, all binding poses of training and test 
set were combined with the predictive set of actives excluded from the modeling process. 
The trained QSAR model was used to assign QSAR scores to all poses which were then 
ranked by this score (Figure 4.2e).  The atoms within 4Å of the catalytic center with the 
top-3 SMARTCyp scores for each pose were assigned modified QSAR scores using the 
following formula:  
𝐹𝑆𝐴 = 𝑄𝑠𝑐𝑜𝑟𝑒 + 
𝐶𝑌𝑃𝐴−𝐶𝑌𝑃𝑅𝐸𝐹
10
       (4.5) 
where FSA is the final score for atom A, Qscore is the QSAR score for the pose in which 
atom A is found, CYPA is the SMARTCyp score for atom A, and CYPREF is the 
SMARTCyp score for the atom used in the QSAR model building process .  This formula 
adjusts the QSAR score for the difference in SMARTCyp scores between the top three 
SMARTCyp atoms (Figure 4.2f).   The lowest score for any given atom among all poses 
was identified, and then the atoms themselves were sorted by score.  The highest ranked 
known SoM was identified and the percentage of correctly predicted SoMs in the top-1, 









4.3 CYP2C9 Results and Discussion 
4.3.1 SMARTCyp Prediction 
 Several reactivity schemes have been developed to predict SoMs in CYP substrates 
based on the physicochemical properties of the ligand alone2,12. Such ligand-based methods 
are advantageous because they do not require protein structural information and are 
computationally efficient. SMARTCyp is one example of a widely used reactivity based 
method. Potential SoMs are evaluated based on a combination the accessibility of the atom 
within the structure and the estimated energy required to abstract a hydrogen from carbon 
atoms or for an oxygen attack in the case of nitrogen, phosphorus, and sulfur atoms. The 
resultant score is referred to as a SMARTCyp score and is used to rank potential SoMs. 
Recently, a new version of the SMARTCyp program, version 2.4.2, was released with 
parameters specific to CYP2C9 ligands13.  
We generated a 139-ligand data set comprised of all possible rotameric and 
protonation states of 73 unique ligands and evaluated each using SMARTCyp version 
2.4.2 (referred to as SMARTCyp). The atoms of each ligand were ranked according to 
the assigned SMARTCyp reactivity score and the number of correctly predicted SoMs in 
the top-1, top-2, and top-3 positions was calculated (Table 4.2 - SMARTCyp Alone 
column). SMARTCyp correctly predicted the known SoM at the top-1 position in 42% of 
the ligands tested. In the top-2 and top-3 positions, the prediction percentages increase to 











4.3.2. Static Docking 
 Docking is another approach used to predict potential SoMs in CYP ligands. 
Docking is one of the most widely used techniques in structure-based drug design and 
provides information about potential ligand binding modes. In the biologically active 
conformation within the CYP binding site, the ligand should be positioned in such a way 
that the SoM is in close proximity to the reactive oxygen atom of the heme moiety. In 
theory, if the docking pose is correctly predicted, atoms which are positioned near the 
oxygen atom of the heme are the most likely SoM candidates.  
As a comparison to our new approach, we docked our ligand library into the 
crystal structure of CYP2C9 (PDB ID: 1R9O) using Autodock Vina (Vina). A docking 
pose was considered to be an accurate SoM prediction if the distance between the known 
SoM and the reactive oxygen of the heme moiety was 4Å or less. Docking poses were 
ranked by the internal Vina scoring function and the percentage of correctly predicted 
SoMs in the top-1, top-2, and top-3 ranked poses were calculated (Table 4.2 - Vina Alone 
column). In addition to assessing predictions in the top-3 ranked poses, we calculated the 
overall docking success by determining the percentage of ligands that achieved an active 
pose regardless of rank (Table 4.2- Vina Alone column).   
SMARTCyp outperformed docking in identifying the known SoM within the top-
3 positions. However, the overall docking success was approximately equal to the 
prediction success of SMARTCyp in the top-3 positions (64% and 67% respectively). This 
highlights two possible shortcomings in the standard Vina docking approach. First, despite 
67% overall accuracy in docking, less than half of these poses were ranked in the top-3 








biologically active conformations in the top positions. Second, the failure to achieve 100% 
docking success suggests that the binding pocket of the crystal structure alone may not be 
able to accommodate the structural diversity of the ligands in the data set.   
It is well known that CYP enzymes are highly flexible and that the binding sites of 
these enzymes often have to adapt to accommodate structurally different ligands14. The 
plasticity of the CYP binding sites can make docking to these enzymes challenging and 
often ensemble approaches are employed to improve docking results15,16. 
 
4.3.3 Ensemble Generation and Selection 
4.3.3.1 Ensemble Diversity 
A pseudo-apo ensemble was generated by extracting 100 snapshots from a 10ns 
trajectory of CYP2C9 with the crystal ligand removed. A principle component analysis 
(PCA) suggests that through the duration of the simulation, both the overall protein 
structure and the binding site residues adopted several alternative conformations (Figures 
4.3a and 4.3b). Ultimately, the increased diversity in the pseudo-apo ensemble allowed for 

























Figure 4.3: Principal component analysis of CYP2C9 pseudo-apo MD trajectories. The 
PCA using all protein residues (a) and only the binding site residues (b).  The binding site 
residues were manually defined based on the defined binding site box from the docking 









For instance, no active docking pose was found for 9-cis-retinoic acid in the crystal 
structure, however side-chain rotations that occurred during the pseudo-apo simulation 
allowed for successful docking of this ligand (Figure 4.4a). The orientation of LEU 208, 
PHE 476, and PHE 100 ( PHE 100 was omitted from figure for clarity) are crucial to 
achieve a bioactive conformation of this ligand. In the crystal structure, the top-ranked 
bioactive pose of the ligand directly overlaps with LEU 208. Furthermore, the rotation of 
ASP 293 in the pseudo-apo simulation provides a potential hydrogen bonding site for the 
ligand.  
Additionally, the binding of torsemide required a significant rearrangement of 
residues in the active site (Figure 4.4b).  A ~3Å shift in the C-terminal loop is accompanied 
by the ~180 degree rotation of PHE476 in the pseudo-apo simulation which allows for this 
ligand to be successfully docked. In the closest-to-active pose in the crystal structure 
docking the ligand is found to occupy a pocket created between the C-terminal loop and 
the G helix, resulting in a conformation where the SoM is 4.2Å from the reactive oxygen. 
In the pseudo-apo simulation, shifting of the C-terminal loop causes a closure of this pocket 
and causes the ligand to bind on the opposite side of the C-terminal loop where the SoM is 
















Figure 4.4: Conformational adaptation in the pseudo-apo simulation that allows for 
successful docking of 9-cis-retinoic acid and torsemide. The true SoM for each ligand has 
been denoted with a sphere. Compared to the flurbiprofen-bound crystal structure (shown 
in dark grey sticks and cartoon), several residues and the C-terminal loop adapt to allow 
for ligand binding. In the case of 9-cis-retanoic acid (a), LEU208 and PHE 476 rotate to 
allow for the ligand to fit into a bioactive conformation. Furthermore ASP293 rotates into 
a position to allow a potential hydrogen bond to the imidazole ring. In the case of torsemide 
(b), a ~180º rotation of the side chain and a >3Å shift in the C-alpha position of PHE 476 
was observed, allowing for a bioactive conformation of torsemide that was not observed in 
the crystal structure. This shift closes a pocket between the C-terminus and the G helix (not 
shown). The closest-to-active pose found in the crystal structure docking was found to 
occupy this pocket. Closure of this pocket allows for an alternative ligand conformation to 









4.3.3.2 Final Ensemble Selection 
While, the inclusion of a variety of binding site conformations may be essential for 
docking of large and diverse ligand libraries such as the one tested here, an ensemble of 
several hundred members is both cumbersome and redundant; therefore the pseudo-apo 
ensemble was further refined.  
A docking filter was used to select the most relevant conformations from the initial 
ensembles. Using a subset of 14 ligands and the fitness function described in the Methods 
section, the top-6 structures from the pseudo-apo ensemble were selected as the final 
ensemble members. The fitness scores, RMSD to the crystal structure, as well as the 









Table 4.1: Calculated fitness score, overall RMSD to 1R9O crystal structure and binding 
site volume of selected ensemble members. The volume of the binding site over the 









PA 97 2.66 1.18 361 
PA 19 2.58 1.19 393 
PA 66 2.58 1.02 422 
PA 1 2.55 1.12 836 
PA 25 2.53 1.18 363 










The 14-ligand training set was initially docked to all protein structures (Figure A1). 
Although some individual members of the ensemble perform worse than the crystal 
structure alone, taken together, ensemble docking shows significant improvement over 
docking to the crystal structure alone. The crystal structure successfully docked only half 
of the 14-ligand test set whereas the pseudo-apo ensemble docked successfully 13 out of 
14 compounds into the top-5 protein structures alone (Figure 4.5). The remaining ligand, 
2-oxoquazepam was successfully docked to the 34th ranked structure.    
The selected ensemble members were found to be structurally diverse and to cover 
a significant portion of the conformational space sampled by the MD simulation according 
to the PCA (Figure 4.3).  Compared to randomly selected ensembles of the same size, the 
filtered ensemble provides considerable improvement in the docking results in the top-3 
positions and slight improvement in the overall prediction success (Table 4.2). The 
improvement over random selection indicates that the pre-filtering procedure aids in the 

























Figure 4.5: A visual representation of the docking performance in a) the crystal structure, 
b) the pseudo- ensemble using the 14-ligand subset. Ligand ranking is indicated by the 
shade of red, lighter regions indicate highly ranked poses, while black indicates that no 
pose was found in which the true SoM was within a reactive distance to the oxygen on the 
heme. The rank of the protein structure according to the fitness function is shown on the 









4.3.4 Ensemble Docking 
Following the selection of the 6-member pseudo-apo ensemble, we used Vina to 
dock all 73 compounds in the data set to each member of the ensemble. Compared to the 
crystal structure alone, the ensemble offered significant improvement in the top-1, top-2 
and top-3 positions and in the overall docking success (Table 4.2).  
 The more diverse binding pockets of the mixed ensemble are likely responsible for 
the significant improvement in the overall docking success. The increase in accurate 
predictions in the top-1, top-2 and top-3 positions, while significant, does not match the 
improvement in overall docking success. The increased binding pocket diversity in the 
ensemble is likely the reason that more compounds can be successfully docked, however, 
this diversity can also result in a higher number of alternative ligand poses, making the 
identification of true positive poses more challenging for the docking scoring function. 
This is one possible reason that the individual increase in the top-1, top-2, and top-3 









Table 4.2: Comparison of various methods for predicting SoMs in the top-1, top-2, and 
top-3 positions. 
 X-ray structure aloneh 









Top-1 12% 44% 21% 38% 49% 
Top-2 24% 59% 27% 53% 56% 
Top-3 38% 68% 37 % 60% 63% 
% docked  64% Gamma 
0.0g 
 
  Pseudo-apo Ensemblei 

























a Percentage of correctly predicted SoMs if a heavy atom was chosen at 
random for each ligand.  
b Percentage of correctly predicted SoMs using SMARTCyp only.  
c Percentage of correctly predicted SoMs using Autodock Vina alone. A 
prediction was considered “correct” if the true SoM was within 4.0Å in the 
top-1, top-2 or top-3 ranked docking poses, respectively.  
d Percentage of correctly predicted SoMs using a combination score 
comprised of the Vina score and the SmartCyp score, see Methods section for 
full details.  
e Percentage of correctly predicted SoMs using the modified QSAR model 
that includes the poses provided by Vina docking and the reactivity scores 
from SMARTCyp. 
f Bracketed values represent the percentage of successfully docked 
compounds when the protein structures that comprised the ensembles were 
chosen at random.  These values represent the average and standard deviation 
over three randomly selected protein sets.  
g Although a gamma (γ) of 0 is selected, the omission of some atoms due to 
failure to find both a successful docking pose and SMARTCyp score can 
result in slightly different rankings using the CS versus SMARTCyp. These 
differences were caused by the inability to find a successful docking pose, 








approach, which can result in slight changes in the overall rankings as 
observed in the crystal structure. 
h Binding poses were identified using docking with AutoDock Vina to the x-
ray structure of CYP2C9 only. 
i Binding poses were identified using docking with AutoDock Vina to an 
ensemble of proteins structures generated by an MD simulations based on the 









4.3.5 Combining Docking and SMARTCyp 
We hypothesized that SoM predictions could be further improved by combining the 
structural data from docking and the ligand-based reactivity predictions from SMARTCyp. 
For instance, let us assume that SMARTCyp incorrectly predicts a given atom as the true 
SoM; although the incorrectly predicted atom may be a highly reactive, it may not be a 
structurally feasible SoM based on its binding conformation. For example, it may be part 
of a bulky group that cannot easily fit close to the reactive oxygen of the heme. By 
including contributions from both docking and SMARTCyp, such atoms could be re-
ranked or even eliminated as possible SoMs, resulting in improved predictions. 
The optimized gamma value can offer insight about the individual contributions 
of docking scoring and SMARTCyp to the overall ranking of the SoM; a low gamma 
suggests that SMARTCyp dominates the calculated CS and docking only provides a 
minor contribution, a gamma of around 10 would suggest approximately equal 
contributions of both docking and SMARTCyp, and a large gamma would suggest that 
docking dominates the CS function.  
In the crystal structure, the optimized gamma value of 0.0 suggests that the results 
are entirely dominated by the SMARTCyp rankings of the compounds. On the other 
hand, the gamma score for the pseudo-apo ensemble is 23.5, suggesting that docking 
scores are a major contribution to the overall CS ranking. There are several reasons for 
this discrepancy in gamma scores. Most notably, in the pseudo-ensemble the rankings of 
SMARTCyp and docking are approximately equal in the top-3 positions (~65%).  This 
suggests that both docking and SMARTCyp have approximately equal ability to 








docked to the ensemble, indicating that docking has the potential to further improve SoM 
prediction above the ~65% observed with either approach individually.  This is in 
contrast to the crystal structure where docking has a significantly lower percentage of 
compounds ranked in the top-3 (~45%) and also a lower overall docking success (~65%), 
thus a less significant potential to contribute to the overall CS ranking.  
In Figure 4.6, we provide some specific examples of how CS ranking in the 
pseudo-apo ensemble improved SoM prediction in various compounds. In some 
compounds, such as galangin, the contribution of the docking score was essential for the 
top-1 CS ranking of the compounds (Figure 4.6a), whereas in others, like terbinafine, it 
was the SMARTCyp (Figure 4.6b) score that was the determining factor. SMARTCyp 
and docking did not rank the same ligands in the top-3 positions as was seen with 
galangin and terbinafine. These differences allowed for approximately 10% improvement 
in the CS ranking. However, the most intriguing cases were those in which different 
rankings of individual atoms by SMARTCyp and docking led to a synergistic ranking 
effect. In these cases, the CS ranking of the true SoM was higher than in either approach 
individually. Suprofen, for example shows this trend (Figure 4.6c). Suprofen and other 
ligands where there was a synergistic effect accounted for the remaining ~10% 































Figure 4.6: The combined score (CS) versus docking and SMARTCyp scores individually 
of the top-3 atoms as ranked by the CS. The top-ranked docking pose is shown on the left 








ranked pose is the bioactive pose, thus only a single pose is shown.  True SoMs have been 
denoted in the text with a star and in the structures as an orange sphere.  a) In some cases 
the docking score is the determining factor for the overall CS ranking of the true SoM. In 
fluvistatin, for instance, in the top ranked docking pose the true SoM, C25, was the atom 
nearest to the reactive oxygen of the heme. Even when combined with a poor SMARTCyp 
score, the favorable docking score of this pose allowed this atom to be ranked 1st overall. 
In other cases, SMARTCyp is crucial for the ranking using CS. In the case of mestranol, 
the top-ranked docking pose places C10 and C14 nearest to the reactive oxygen (b). 
However, these atoms were ranked poorly by SMARTCyp (4th and 5th, respectively). The 
top-ranked bioactive pose (c) had a docking score that was only slightly less favorable than 
the top ranked pose, and thus when combined with the SMARTCyp scores, wherein the 
true SoM was ranked first, the overall CS ranking placed the true SoM in the top-1 position.  
In some cases there was a synergistic outcome using the CS. In GV150526, SMARTCyp 
incorrectly predicts the SoM as C3, however the docking results suggest that the 
conformation leading to metabolism of C3 is unfavorable (ranked 15th overall). The overall 
top-ranked pose (d) incorrectly predicts O14 as the true SoM, however this atom was not 
favorably ranked using SMARTCyp. The top-ranked bioactive pose (e) ranks the true SoM 
4th overall and SMARTCyp ranks this atom 2nd overall. Combining these predictions leads 








Although using a combination approach in the pseudo-apo ensemble improved 
performance over either SMARTCYP alone or docking alone, and all approaches tested 
on the crystal structure alone, we hypothesized that using Quantitative Structure-Activity 
Relationship (QSAR) modeling could improve the separation between active and inactive 
docking poses and further improve SoM prediction in the top-1, top-2, and top-3 
positions.  
 
4.3.6 Ranking CS data using QSAR 
QSAR is a computational method that derives statistical relationships between 
sets of descriptors, typically ligand properties, and a set of values, typically the biological 
activities of the target ligands.  We hypothesized that there were certain key ligand 
features, along with the spatial orientation of those features, which could distinguish 
between active and decoy docking poses, and that QSAR statistical modeling could be 
used to identify those features.  By assigning a favorable score to active poses as 
compared to decoy poses, we aimed to train a model to preferentially select active ligand 
poses. 
However, in addition to protein-ligand interactions, for CYP metabolism the 
reactivity of a chemical group is an additional critical factor to determine the potential 
SoM of a ligand. As pseudo-receptor QSAR programs, such as RAPTOR, do not directly 
incorporate this factor, we modified RAPTOR to include SMARTCyp scores as a 
descriptor in the modeling process. Using this modified QSAR approach, we were able to 








Compared to SMARTCyp alone, docking alone, or the combined approach using 
SMARTCyp and docking (CS), re-ranking atoms using QSAR proved to be far superior. 
For example, the QSAR model based on the docking results from the pseudo-apo 
ensemble was able to predict the correct SoM in 88% and 96% within the top-1and top-2 
positions, respectively.  
For several compounds the QSAR approach drastically improved the ranking of 
the true SoM in comparison to the other methods tested (Figure 4.7). For instance, for 
etodolac (Figure 4.7a and 4.7b) none of the other methods tested accurately predicted the 
true SoM, C13, within the top-3 positions. However, using QSAR, the top ranked pose 
placed the true SoM within 4.0Å of the reactive oxygen. Notably, this pose was very 
poorly ranked using docking (10th overall). In other compounds, such as 17 alpha-
ethinylestradiol (Figure 4.7c and 4.7d), the QSAR score offered incremental 
improvements within the top-3 ranked positions. In this compound, both docking and 
SMARTCyp were unable to rank the true-SoM within the top-3 positions. While the CS 
method improved the ranking to the top-2 position, QSAR ranked the true SoM at the 
























Figure 4.7: Examples of compounds in which the QSAR method improves SoM prediction 
over other tested methods. In the left column is the pose selected by the QSAR model and 
in the right column is the top-ranked docking pose, in both cases the true SoM has been 
shown in an orange sphere. The transparent white sticks represent the conformation of the 
crystal structure. In the case of Etodolac, the top ranked QSAR and top-ranked docking 
pose both have the true SoM oriented towards the reactive oxygen, but the QSAR pose 
selects the structure in which the SoM is within a reactive distance (a and b). For17 alpha-
ethinylestradiol, the QSAR model selects a pose that is completely inverted (c) from the 
top-ranked docking pose (d). In both cases, the QSAR model places the known SoM in the 
top-1 predicted position. Notably, in all cases successful ligand docking requires a 
significant rearrangement of the binding site residues, as neither of these compounds could 









One remaining limitation for the success of the QSAR model was the overall 
docking success. In other words, assuming that an active pose was sampled during the 
docking process, the QSAR model was nearly always able to identify the true SoM 
within the top-3 positions. In the crystal structure for instance, the QSAR model 
accurately predicted the SoM within the top-3 positions for all but one of the compounds 
for which an active docking pose was obtained.  For the pseudo-apo ensemble, all 
compounds with an active docking pose were predicted within the top-2 ranked SoM. 
Table 4.3 represents the QSAR results in isolation, i.e. only ligands for which 
active docking poses were found are considered.  In this situation, 91%, 100% and 100% 
of the known SoMs are correctly predicted when the pseudo-apo ensemble was used for 
docking within the top-1, top-2 and top-3, respectively.  These percentages are slightly 
lower when the crystal structure was used for docking, i.e., 77%, 87%, and 98%, for the 
top-1, top-2, and top-3 positions, respectively.  
While the QSAR model using the results from docking to the crystal structure was 
severely limited by the quality of the docking process, the pseudo-apo docking set was 
able to generate active poses for most ligands, allowing the subsequent QSAR model to 








Table 4.3: QSAR SoM Rankings of ligands with an active docking pose. 
 
Fraction of Ligands with 
Rank 
Total Number of Active 
Ligands 
 QSAR Model Top 1 Top 2 Top 3 
X-ray 0.77 0.87 0.98 47 
Pseudo-apo 










Over-fitting can be a concern in QSAR modelling, so the results for the test and 
training set of the QSAR models were compared (Table 4.4).  Similar to Table 4.3, only 
those ligands for which an active docking pose was found are included in the 
comparisons.  For the x-ray structure, there was little differences between the two sets; 
the training and test set had approximately the same fractions in the top-1, top-2, and top-
3 positions.  For the pseudo-apo ensemble, the prediction accuracy of the test set 
exceeded  that of the training set, where the SoM of all ligands was correctly predicted in 
the top-1 position.   This indicates that the chemical space of the test set was well-
covered by the training set, and that the model has high predictive power for future 
compounds within the space modeled. 
Additionally, as the RAPTOR QSAR package generates a pseudo-receptor model 
of the protein binding pocket around the ensemble of ligand poses, we visually compared 
the QSAR model with the members of the pseudo-apo structural ensemble, a 
representative example is shown in Figure 4.8. As shown, there is significant agreement 
between the protein structure and the RAPTOR model.  Where the model predicts 
hydrophobic properties, the protein residues are mainly hydrophobic, such as LEU 366 
and 361, and PHE 100, 114, and 476.  Hydrophilic residues such as ARG 108, ASN 204, 
and ASP 293 are collocated with hydrophilic features of the RAPTOR pseudo-
receptor.  PHE 100 and 114 both appear to be able to engage in different types of 
interactions, as they are co-located with both hydrophobic and hydrophilic features, 








Table 4.4: Comparison of QSAT Test and Training Sets. 
 
Fraction of Training Set 
Ligands with Rank 
Total Number of 
Active Ligands 
 QSAR Model Top 1 Top 2 Top 3 
X-ray, training 0.76 0.88 1.00 33 
X-ray, test 0.79 0.86 0.93 14 
     
Pseudo-apo, training 0.88 1.00 1.00 51 











Figure 4.8:   The QSAR model of the pseudo-apo data set.  The binding site residues (a) 
and pseudo-receptor (b) with 90º rotation (c) generated by RAPTOR. The pseudo-receptor  
RAPTOR models are colored by property, with red representing hydrogen bond acceptors, 












4.4 CYP2C9 Conclusions 
In this study, we compared the ability of ligand-based, structure-based, and 
combination-based approaches to predict the SoM in 73 diverse CYP2C9 substrates. Of 
all individual methods tested, docking was found to have the poorest performance. 
Whereas ensemble docking showed a significant improvement over docking to the crystal 
structure alone, at most 38% of the compounds were ranked in the top-1 position using 
docking.  Using the SMARTCyp reactivity model alone, 42% of the compounds were 
accurately prediction in the top-1 position. By combining the docking scores and 
SMARTCyp scores prediction accuracy was improved in both ensembles, but not in the 
crystal structure. Ultimately, we found that the inclusion of QSAR into the combination 
approach resulted in significant improvement in prediction success and was the most 
effective and accurate SoM prediction method tested in this work.  
In all systems tested, the QSAR model was able to accurately predict, within the 
top-3 positions, the SoM for nearly all ligands with an active pose. A key limitation to the 
success observed with QSAR was the ability of docking to provide active poses, in other 
words, poses in which the true SoM was within a reactive distance to the oxygen of the 
heme. Using a pseudo-apo ensemble, we were able to find an active docking pose for 
nearly all ligands tested. To set our results in perspective, a recent study of currently 
published methods found that accurate predictions in the top-2 positions range between 
68-87%, on average, across various CYP isoforms17. In the same study, the highest 
prediction rate achieved for CYP2C9 was 87% in the top-217. Using our approach we 
achieved an accurate prediction rate of 96% in the top-2 positions, albeit using a 








Our promising results in CYP2C9 represent a step towards improved and highly 
accurate SoM predictions in CYP enzymes. While in the current study we tested 
substrates of CYP2C9, we believe that the proposed method will be of use in broader 
ligand datasets and also will be applicable to different CYP isozymes.  
 
4.5 Extension of method to other CYP Isozymes 
 The general ligand preparation procedure for the other CYP isozymes was identical 
to the method used to prepare the CYP2C9 set.  The size of the ligands sets for the CYPs 
is as follows: 1A2 (271 Ligands), 2A6 (105 Ligands), 2B6 (151 Ligands), 2C8 (141 
Ligands), 2C19 (218 Ligands), 2-D6 (270 Ligands), 2E1 (145 Ligands), 3A4 (475 Ligands).  
The rest of the methods used to generate the SoM prediction models follow the same 
procedure as section 2 of this chapter with two major exceptions. 
 The first change is with regards to the ligands used to select the representative 
protein ensemble members.  For 2C9, these ligands were manually selected.  For the other 
data sets, this process was automated.  The ligand sets were clustered based on similarity 
to select structurally diverse ligands.  Generally, the size of the diverse selected was set to 
be approximately 10-20% of the total ligand set.  This guided selection process was used 
for all remaining eight CYP isozymes.  Similarly, for 2C9 the initial selection of the test 
and training sets was random.  This random set was then manually curated for coverage of 
the chemical space of the ligand set.  This process was also automated for the other ligand 
sets using the same clustering method used to select the ensemble selection set, only with 
slightly larger number of clusters.  This process typically resulted in test sets of similar size 








4.6 Results and Comparison for CYP Isozymes 
 As can be in Table 4.5, our models for all CYP isozymes produced highly reliable 
predictions of CYP SoMs.  The Top-1 prediction rates range from 79% for 1A2 to 97% for 
2B6.  The Top-3 prediction rates range from 85.2% for 2-D6 to 100% for 2C8.  The average 
prediction rate across all nine isozymes is 85% in the Top-1, 92% in the Top-2 and 93% in 
the Top-3.  It is important to note that overall docking accuracy was comparable to the 
Top-3 percentage at 94%.  Overall, and for each individual CYP isozyme, the same general 
trend noticed for CYP2C9 was observed: if an active docking pose for a ligand can be 
found, the QSAR model is generally able to place it in one of the top spots. 
 To investigate this issue, a secondary model was built for several of the CYP 
isozymes with the lowest docking accuracy, including CYP2-D6.  For these secondary 
models, those ligands for each CYP isozyme which failed to find an active docking pose 
in the initial model were used as the screening ligands for a repeat of the protein ensemble 
member selection process.  In general, most (over 90%) of the failed ligands successfully 
docked to an ensemble member at this stage.  In addition, there was significant overlap 
between the original protein structure ensembles and the newly selected ensembles.  The 
new structures were added to the original protein ensembles, and the rest of the method 









  Table 4.5: SoM Prediction for Nine Cyp Isozymes 




Top-1 Top-2 Top-3 
1A2 271 93 79 90 91 
2A6 105 94 87 93 93 
2B6 151 99 97 99 99 
2C8 141 100 94 100 100 
2C9 226 96 88 96 96 
2C19 218 88 80 87 88 
2D6 218 87 80 84 85 
2E1 270 96 81 89 91 










However, after the new models were completed, there was no significant change in 
overall docking accuracy or final prediction rates of the models.  Comparing which ligands 
were successfully docked for each model, while most ligands docked successfully to both 
models, some ligands docked successfully to only one model, while some docked to neither.  
This last set was of particular interest, as many of these ligands docked successfully in the 
ensemble selection process. When the results of the ensemble selection process were 
further analyzed, we found a common characteristic:  The ligands that successfully docked 
in the ensemble selection stage did so with low ranks.  We therefore concluded that the 
docking scoring process was a weakness in our method, as it preferred non-active poses 
for some ligands. 
Even with this issue with the docking process, our results compare favorably with 
the top methods in the field.  Table 4.6 is a comparison of the Top-2 prediction percentages 
for our method, along with Xenosite17, RS-Predictor12, and SmartCYP2, along with the 
random prediction rate.  The major difference between CyPredict and the other methods is 
the use of structure-based information.  CyPredict uses both ligand-based and structure-
based methods, while the other methods are purely ligand-based, using quantum chemical 
and topological descriptors.   Our method produced the highest successful prediction rate 
for seven of the nine tested CYP isozymes, with the exceptions being 2C19 and 2-D6.  For 
CYP2C19, our rate was 87% as compared to 89% for Xenosite.  For CYP2-D6, our rate 
was 84% compared to 89% for Xenosite and 86% for RS-Predictor.  For the other isozymes, 
our method performed 3% to 15% better than the next best method, and our average 
prediction rate was 92% compared to 87% for Xenosite, 84% for RS-Predictor, and 82% 








Table 4.6: Comparison of Cyp SoM Prediction Methods 
Method 1A2 2A6 2B6 2C8 2C9 2C19 2D6 2E1 3A4 Ave. 
Lill 90.0 93.0 98.7 100 96.0 87.2 83.7 89.0 90.0 92.0 
Xenosite17 87.1 85.7 83.4 88.7 86.7 89.0 88.5 83.5 87.6 87.0 
RS-
Predictor12 
83.4 85.7 82.1 83.8 84.5 86.2 85.9 82.8 82.3 84.3 
SMARTCyp2 80.0 86.0 77.0 83.0 84.0 86.0 83.0 82.0 78.0 82.1 










Another key factor in these comparisons is the validation method for the models.  
Xenosite used leave-one-out cross-validation, while RS-Predictor and SMARTCyp used 
10-fold validation.  These methods use multiple models with test sets of either one 
compound (leave-one-out) or 10% of compounds (10%).  In comparison, our test sets range 
from approximately 50% to 90% of our ligands.  These large test sets indicate that our 
models have retained significant predictive power while avoiding possible overfitting of 
the data. 
4.7 Conclusions 
With these last studies, we have shown that we are successfully able to extend our 
model to other CYP isozymes beyond 2C9.  Our models compare favorably with the 
current best-performing CYP SoM prediction techniques, and in several cases significantly 
outperform them.  In addition, we have identified a specific area of concern to focus on for 
improving our methods: increasing docking accuracy.  Currently, this is the weakest 
portion of our method, as the pseudoreceptor modeling process is generally able to 
correctly select active ligand poses if one has been generated by the docking process.  
Beyond improving docking, any further improvements in the process will require more 
complex calculations, such as QM/MM methods, as the second largest source of error we 
found is in the SMARTCyp scoring process. 
In addition, the completed CYP models are being made freely available to academic 
users for SoM prediction through a webserver using the Nanohub platform.18 The server 
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CHATER 5. FUTURE DIRECTIONS 
 
5.1 Research Summary 
The overall goal of my research was the application and development of the 
advancement of combined ligand-based and structure-based techniques, namely 
pseudoreceptor-based methods, with a focus on surface-based pseudoreceptors.  While the 
goal of pseudoreceptor methods is to produce a protein-like structure to interact with 
ligands, there has been a lack of use of protein structural data in the guiding of the creation 
of the pseudoreceptors.  In Chapter 2, analysis of the interaction surface between protein 
crystal structure and co-crystallized ligand for the refined set of the PDBbind database was 
presented.   These surfaces represented the ideal pseudoreceptor, as they mapped the true 
interactions of protein and ligand, and the analysis showed that the majority of protein-
ligand interactions can be mapped by a few of Gaussian-based descriptors that have 
parameters that fall into a small range of values.  In Chapter 3, a means of tuning surface-
based pseudoreceptors to accurately replicate protein binding pocket topology as from 
known binding ligands will be presented. 
In Chapter 4, I will discuss the implementation of the refinement of our group’s 
previous work on SoM prediction, which includes the use of a modified version of the 
RAPTOR pseudoreceptor package.  The modification was the inclusion of reactivity scores 








motivation for the inclusion of RAPTOR was as a means of generating a model which 
could reliably select binding poses with the known SoM close to the heme of CYP.  This 
method was implemented as a means to counteract the difficulties arising from the large 
number of poses generated by the ensemble docking process.  The initial modeling was 
performed on CYP2C9, but was later extended to eight other CYP isozymes.  In this final 
chapter, we will discuss several possible methods for continuing or improving upon the 
research discussed in this thesis. 
 
5.2 Pseudoreceptor Method 
To extend the work presented in Chapters 2 and 3, we have worked to implement a 
new pseudoreceptor-based QSAR package based on the RAPTOR package but with 
improvements based on the insights presented in this thesis.  Significant progress has been 
made on this new computational tool, but it has not yet reached completion.  In addition to 
improvements to the pseudoreceptor method, we have also chosen to move to Python from 
the C-based languages for the primary programming language.  Python is well-suited for 
file and data management tasks, but lacks speed for intense computations.  We have used 
weave to integrate fast C code for those portions of the code with large numbers of complex 
calculations.  The method alterations are primarily focused on a Correlated Mutli-surface 












5.2.1 Correlated Multi-surface (CMS) Model 
 After our analysis in Chapter 3, where we determined that a single iso-surface is 
unable to represent the flexible binding pocket of a protein for diverse ligands, we 
developed a CMS model.  Our first thought was to simply use multiple independent iso-
surfaces of varying iso-level values.  Each iso-surface is generated from the ligand 
occupancy values via the Marching Cubes algorithm.  After consideration though, we had 
a number of concerns with this process.  With independent iso-surfaces, even regions where 
the surfaces are very close together, the algorithm could have assigned sets of radically 
different Gaussians to the surfaces, which is not realistic.  If the shells are representing the 
same region and conformation of a protein, they should have identical physico-chemical 
(electrostatic, hydrophobic, hydrogen bond) properties.  To address this, we decided to 
correlate the iso-surfaces if they are physically close to each other.  To determine 
correlation, for each vertex of each iso-surface, the closest vertex (as determined by 
distance scaled by angle between the vertices) of every other iso-surface is found.  If the 
closest vertex is within a certain cut-off, the vertices are then linked to each other, which 
is important when generating the initial Gaussians and in the genetic algorithm. 
 After generating and correlating our multiple iso-surfaces, we generate our initial 
Gaussian regions via the following process.  First, we determine the total strength of every 
ligand atom’s interactions with every shell that contains that atom.  (A shell contains a 
ligand atom if the iso-level of that shell is lower than the occupancy value at that atom’s 
coordinates.)  This strength is determined by the same functions as used for the protein in 
the PLSIA algorithm presented in Chapter 2.  From the ten vertices with the largest value 








parameters, with ranges determined from our previous work.  This Gaussian is then mapped 
to the surrounding surface, and a Gaussian region is determined.  If the surface point where 
the center of the Gaussian is correlated, this Gaussian is propagated to all correlated iso-
surfaces.  All members of the Gaussian region are then excluded, and the ten strongest non-
excluded vertices are found and a new center chosen.  This process repeats up to a 
maximum number of iterations for all properties of all shells, with correlated regions 
counting towards the maximum.  In order to provide more diverse models, the maximum 
number of iterations is randomly determined. 
 
5.2.2 Scoring and Machine Learning 
 The Gaussian-mapped shells are then passed to the machine learning algorithm for 
the creation of the final pseudoreceptor model.  We have implemented the PyEvolve 
genetic algorithm package with customized functions.  We have implemented correlated 
cross-over and mutation functions.  In the cross-over function, the algorithm selects one 
Gaussian from one of the parent models and then swaps that Gaussian and all its correlated 
Gaussians with a set of correlated Gaussians of the appropriate physico-chemical property 
from the other parent.  This cross-over is also restricted by a distance cut-off between the 
locations of centers of the Gaussians: only Gaussians located in the approximately the same 
location may be swapped.  The mutation function also works amongst correlated Gaussians.  
The allowed mutations are addition, deletion, moving the center along a single edge of the 
iso-surface, and change of Gaussian parameter (radius, amplitude, and angle).  These 
mutations are propagated to all correlated Gaussians, and correlated Gaussians are created 








After a certain number of steps, we export the top models from the genetic 
algorithm to a Monte Carlo optimization algorithm along with the initial ligand 
conformations from the alignment process.  In the Monte Carlo process, the ligand 
conformations are allowed to translate as well as rotate.  The best pose for each ligand 
conformation, as scored using the same scoring function as in the genetic algorithm, is 
returned to the pseudoreceptor program for all Monte Carlo models.  The best scored pose 
for each ligand conformation from amongst all the Monte Carlo models is identified and 
selected.  These poses are then used to generate a new pseudoreceptor model (new iso-
surfaces and genetic models) until a set number of iterations of the full process have been 
completed, then the final predictions are generated. 
These processes will be scored by computing the interaction between the fields 
from the Gaussian surfaces directly with the ligand atoms.  Typically, scores are computed 
between the ligand atoms and the discrete grid points.  This point-to-point pairwise scoring 
not only creates a large number of descriptors which can lead to overfitting; it does not 
replicate the surfaces found in actual protein-ligand interactions.  With our process, instead 
of each grid point being independent, regions of the iso-surface are linked by Gaussian 
functions where the properties of the entire region are determined by the four 2-D Gaussian 
parameters.  We are currently scoring the Gaussians with a simple modified piece-wise 
linear pairwise (PLP) scoring function combined with an electrostatic term.  The 
electrostatics are computed by computing the pairwise Coulombic interaction between the 
ligand atoms and the iso-surface vertices of electrostatic Gaussians.  Hydrophobic, steric, 
and hydrogen bond terms are calculated using a modified PLP function (Gehlhaar, 1995).  








between ligand atoms and the iso-surface vertices appropriate Gaussian regions, except the 
steric term is calculated with the full iso-surface instead of Gaussian regions.  The 
individual interactions are then scaled according the Gaussian value of the vertex. 
 
5.3 CYP SoM Prediction 
 As illustrated in Chapter 4, we have achieved significant success with our algorithm 
for the prediction of SoMs for a number of CYP isozymes, but we also feel there are 
potential avenues to improve and extend the method.  First, as mentioned previously, one 
major issue is docking accuracy, which is typically less than 100% for the CYP isozymes.  
Second, while we have tested the performance on a single CYP isozyme at a time, we have 
not explored trying to predict SoM’s against multiple CYP isozymes simultaneously. 
 
5.3.1 Docking Accuracy 
 As previously mentioned, with our method, if we can obtain an active docking pose, 
the pseudoreceptor model can generally identify that pose.  Therefore, the major source of 
error for our models is in the docking process.  We found that increasing the number of 
protein ensemble members was not successful in remedying this issue.  This is supported 
by our studies of CYP2C9, where we found insignificant increase in model accuracy when 
using more than six protein structure models.  The other CYP isozymes seem to follow this 
trend, adding structures above a certain minimum does not significantly improve docking 
accuracy. 
 During our analysis of our results, we found the ligands that were not always 








take the top ten ligand poses into consideration, and the active poses for these ligands are 
generally ranked close to ten if successfully docked at all.  Therefore, to increase docking 
accuracy, one possible solution is to increase the number of generated docking poses.  This 
is not an ideal solution, as this increases the number of poor poses for those ligands for 
which we can find active poses in the top ten.  This can eventually cause difficulties for the 
pseudoreceptor modeling process.  Another possible solution is iterating the docking 
process.  As we know from our previous studies, we can occasionally find active poses 
from the difficult ligands.  Therefore, if we run the docking process multiple times, an 
active pose may be generated.  As we would still only generate the top ten poses for each 
iteration, the ratio of active to decoy poses should remain relatively constant, which should 
theoretically be favorable to purely increasing the number of accepted poses.  That is, while 
both processes could decrease QSAR accuracy due to an increased number of docking 
poses, the iterative process should have a better ratio of active to decoy poses, so long as 
the docking scoring process is better than random and an equivalent total number of poses 
are generated..  Extensive docking studies are needed to determine which method is 
preferred, as it is dependent on both how likely we are to find an active pose at a given 
rank, and how this changes when the total number of ranks is increased.  Another 
alternative is an additional docking processing step where the poses are scored with a more 
accurate function, such as MM/PBSA or MM/GBSA.  While using more sophisticated 
scoring function would increase the computational cost of docking, it might be possible to 










5.3.2 CYP Selectivity 
 The percentage of approved drugs that the CYP isozymes, studied in this thesis, 
metabolize was discussed in Chapter 4.  The sum of these percentages is well above 100%, 
which is indicative of one of the issues of metabolism: multiple metabolic pathways.  In 
our studies, we have only worked with known ligands for each CYP isozyme.  While being 
able to reliably predict where each isozyme will metabolize a ligand, it is also important to 
be able to predict which isozymes will metabolize a given ligand. 
 In order to assess the ability of our method to address this problem, instead of using 
a tailored ligand set for each isozyme, we will repeat our studies with a combined ligand 
set formed from the individual isozyme sets.  For each isozyme, those ligands that are not 
known to be metabolized by that isozyme will have all their docking poses classified as 
decoy poses.  The selectivity of our method for each isozyme will then be determined by 
analyzing the scores of the known ligands, most likely using a method such as a receiver 
operating characteristic curve.  This analysis would give a score of one if our method scores 
all known metabolites ahead of all known inactive compounds, and gives a score of zero 




























Table A1: Protein systems and corresponding pdb codes 
 











































Protein System PDB Entries 

































Table A2: Occupancy Distribution of Estrogen Receptor 
 
c-value Fraction of surface points with target occupancy 
1.4 0.001 0.072 0.183 0.167 0.153 0.126 0.096 0.073 0.044 0.026 0.017 0.015 0.008 0.009 0.006 0.002 0.001 0.002 0.000 0.000 0.000 0.000 
2 0.000 0.012 0.052 0.083 0.102 0.122 0.128 0.112 0.106 0.081 0.074 0.045 0.029 0.018 0.016 0.008 0.005 0.005 0.002 0.000 0.000 0.000 
2.5 0.000 0.002 0.028 0.033 0.041 0.067 0.091 0.103 0.118 0.111 0.103 0.090 0.084 0.050 0.027 0.020 0.014 0.012 0.003 0.002 0.000 0.000 
3 0.000 0.000 0.016 0.030 0.016 0.017 0.044 0.068 0.081 0.104 0.122 0.115 0.111 0.095 0.077 0.045 0.027 0.017 0.009 0.005 0.000 0.000 













Table A3: Cumulative Occupancy of Estrogen Receptor 
 
c-value Cumulative Occupancy Fraction 
1.4 1.000 0.999 0.927 0.744 0.577 0.424 0.298 0.202 0.129 0.085 0.059 0.042 0.028 0.019 0.011 0.005 0.003 0.002 0.000 0.000 0.000 0.000 
2 1.000 1.000 0.988 0.936 0.854 0.751 0.630 0.502 0.390 0.284 0.203 0.128 0.084 0.055 0.036 0.021 0.013 0.008 0.003 0.000 0.000 0.000 
2.5 1.000 1.000 0.998 0.969 0.936 0.895 0.827 0.737 0.634 0.516 0.406 0.302 0.212 0.128 0.078 0.051 0.031 0.017 0.005 0.002 0.000 0.000 
3 1.000 1.000 1.000 0.984 0.954 0.939 0.922 0.877 0.809 0.729 0.624 0.502 0.387 0.275 0.180 0.103 0.058 0.031 0.014 0.005 0.000 0.000 



















c-value Fraction of surface points with target occupancy 
1.4 0.049 0.146 0.151 0.147 0.137 0.114 0.088 0.064 0.044 0.026 0.016 0.009 0.005 0.002 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
2 0.011 0.095 0.090 0.083 0.089 0.102 0.108 0.105 0.089 0.072 0.059 0.042 0.028 0.017 0.008 0.003 0.000 0.000 0.000 0.000 0.000 0.000 
2.5 0.001 0.059 0.063 0.063 0.059 0.066 0.077 0.092 0.098 0.096 0.092 0.076 0.064 0.045 0.028 0.015 0.005 0.001 0.000 0.000 0.000 0.000 
3 0.000 0.029 0.045 0.048 0.048 0.048 0.051 0.065 0.076 0.091 0.096 0.100 0.094 0.081 0.060 0.043 0.021 0.006 0.000 0.000 0.000 0.000 












Table A5: Cumulative Occupancy of HIV-PR 
 
c-value Cumulative Occupancy Fraction 
1.4 1.000 0.951 0.805 0.654 0.507 0.369 0.255 0.167 0.103 0.059 0.032 0.016 0.007 0.002 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
2 1.000 0.989 0.894 0.804 0.721 0.632 0.530 0.422 0.317 0.228 0.156 0.097 0.055 0.027 0.010 0.003 0.000 0.000 0.000 0.000 0.000 0.000 
2.5 1.000 0.999 0.941 0.878 0.815 0.755 0.689 0.612 0.520 0.422 0.326 0.234 0.158 0.094 0.049 0.021 0.005 0.001 0.000 0.000 0.000 0.000 
3 1.000 1.000 0.971 0.927 0.879 0.831 0.783 0.732 0.668 0.592 0.500 0.404 0.305 0.211 0.130 0.071 0.028 0.006 0.000 0.000 0.000 0.000 












Table A6: Occupancy Distribution of CDK-20 
 
c-value Fraction of surface points with target occupancy 
1.4 0.014 0.182 0.221 0.150 0.105 0.077 0.062 0.051 0.043 0.037 0.026 0.018 0.009 0.003 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
2 0.003 0.095 0.143 0.136 0.125 0.097 0.082 0.069 0.058 0.048 0.040 0.038 0.030 0.023 0.010 0.003 0.000 0.000 0.000 0.000 0.000 0.000 
2.5 0.000 0.058 0.095 0.097 0.108 0.105 0.096 0.080 0.073 0.061 0.052 0.044 0.042 0.038 0.029 0.017 0.005 0.000 0.000 0.000 0.000 0.000 
3 0.000 0.033 0.070 0.063 0.077 0.096 0.093 0.094 0.079 0.076 0.066 0.057 0.047 0.045 0.044 0.037 0.020 0.003 0.000 0.000 0.000 0.000 















Table A7: Cumulative Occupancy of CDK-20 
 
c-value Cumulative Occupancy Fraction 
1.4 1.000 0.986 0.804 0.583 0.433 0.328 0.251 0.189 0.138 0.095 0.058 0.031 0.013 0.003 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
2 1.000 0.997 0.902 0.759 0.623 0.499 0.402 0.320 0.251 0.193 0.146 0.105 0.067 0.037 0.014 0.004 0.000 0.000 0.000 0.000 0.000 0.000 
2.5 1.000 1.000 0.942 0.846 0.750 0.642 0.537 0.440 0.361 0.288 0.227 0.175 0.131 0.089 0.051 0.022 0.005 0.000 0.000 0.000 0.000 0.000 
3 1.000 1.000 0.967 0.897 0.834 0.757 0.662 0.569 0.475 0.395 0.319 0.253 0.196 0.149 0.104 0.060 0.023 0.003 0.000 0.000 0.000 0.000 



















Table A8: Occupancy Distribution of CDK-10 
c-value Fraction of surface points with target occupancy 
1.4 0.043 0.160 0.188 0.153 0.102 0.072 0.058 0.045 0.043 0.037 0.032 0.026 0.019 0.010 0.007 0.003 0.002 0.000 0.000 0.000 0.000 0.000 
2 0.022 0.088 0.112 0.133 0.116 0.097 0.076 0.060 0.052 0.048 0.042 0.041 0.035 0.030 0.023 0.013 0.008 0.003 0.001 0.000 0.000 0.000 
2.5 0.012 0.055 0.072 0.088 0.106 0.102 0.087 0.076 0.064 0.053 0.052 0.049 0.043 0.043 0.035 0.030 0.019 0.010 0.004 0.000 0.000 0.000 
3 0.008 0.034 0.050 0.060 0.072 0.084 0.095 0.082 0.074 0.067 0.058 0.054 0.053 0.050 0.047 0.042 0.035 0.022 0.010 0.002 0.000 0.000 















Table A9: Cumulative Occupancy of CDK-10 
 
c-value Cumulative Occupancy Fraction 
1.4 1.000 0.957 0.797 0.608 0.456 0.354 0.282 0.223 0.178 0.135 0.098 0.066 0.040 0.021 0.012 0.005 0.002 0.000 0.000 0.000 0.000 0.000 
2 1.000 0.978 0.890 0.778 0.645 0.529 0.432 0.356 0.296 0.244 0.196 0.154 0.112 0.077 0.047 0.024 0.012 0.004 0.001 0.000 0.000 0.000 
2.5 1.000 0.988 0.933 0.860 0.772 0.666 0.564 0.477 0.401 0.338 0.284 0.232 0.183 0.140 0.097 0.063 0.033 0.014 0.004 0.000 0.000 0.000 
3 1.000 0.992 0.958 0.908 0.848 0.776 0.692 0.597 0.515 0.441 0.374 0.315 0.261 0.208 0.158 0.112 0.069 0.034 0.012 0.002 0.000 0.000 













Table A10: Occupancy Distribution of CDK-5 
 
c-value Fraction of surface points with target occupancy 
1.4 0.080 0.168 0.154 0.126 0.098 0.073 0.056 0.050 0.045 0.036 0.034 0.032 0.022 0.012 0.007 0.004 0.002 0.000 0.000 0.000 0.000 0.000 
2 0.040 0.102 0.100 0.100 0.100 0.093 0.079 0.068 0.056 0.050 0.045 0.042 0.036 0.032 0.027 0.017 0.008 0.004 0.001 0.000 0.000 0.000 
2.5 0.024 0.068 0.065 0.075 0.081 0.081 0.086 0.080 0.074 0.066 0.055 0.049 0.046 0.040 0.034 0.034 0.025 0.012 0.005 0.001 0.000 0.000 
3 0.013 0.045 0.049 0.051 0.060 0.065 0.071 0.078 0.080 0.077 0.074 0.063 0.054 0.049 0.043 0.041 0.042 0.030 0.012 0.003 0.000 0.000 
Occupa
ncy 0.000 0.025 0.075 0.125 0.175 0.225 0.275 0.325 0.375 0.425 0.475 0.525 0.575 0.625 0.675 0.725 0.775 0.825 0.875 0.925 0.975 1.000 
 


















Table A11: Cumulative Occupancy of CDK-5 
c-value Cumulative Occupancy Fraction 
1.4 1.000 0.920 0.751 0.597 0.471 0.373 0.300 0.244 0.194 0.149 0.114 0.080 0.048 0.026 0.014 0.007 0.003 0.000 0.000 0.000 0.000 0.000 
2 1.000 0.960 0.858 0.758 0.658 0.558 0.465 0.387 0.318 0.262 0.212 0.167 0.126 0.090 0.058 0.031 0.014 0.005 0.001 0.000 0.000 0.000 
2.5 1.000 0.976 0.908 0.843 0.768 0.687 0.606 0.520 0.441 0.367 0.301 0.246 0.196 0.151 0.111 0.077 0.043 0.018 0.006 0.001 0.000 0.000 
3 1.000 0.987 0.941 0.892 0.842 0.782 0.717 0.646 0.568 0.488 0.410 0.336 0.273 0.219 0.171 0.128 0.087 0.045 0.015 0.003 0.000 0.000 
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